ID   POL_HV1B1               Reviewed;        1447 AA.
AC   P03366; P03368;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   24-JUN-2015, entry version 196.
DE   RecName: Full=Gag-Pol polyprotein;
DE   AltName: Full=Pr160Gag-Pol;
DE   Contains:
DE     RecName: Full=Matrix protein p17;
DE              Short=MA;
DE   Contains:
DE     RecName: Full=Capsid protein p24;
DE              Short=CA;
DE   Contains:
DE     RecName: Full=Spacer peptide 1 {ECO:0000250|UniProtKB:P12497};
DE              Short=SP1;
DE     AltName: Full=p2;
DE   Contains:
DE     RecName: Full=Nucleocapsid protein p7;
DE              Short=NC;
DE   Contains:
DE     RecName: Full=Transframe peptide;
DE              Short=TF;
DE   Contains:
DE     RecName: Full=p6-pol;
DE              Short=p6*;
DE   Contains:
DE     RecName: Full=Protease;
DE              EC=3.4.23.16;
DE     AltName: Full=PR;
DE     AltName: Full=Retropepsin;
DE   Contains:
DE     RecName: Full=Reverse transcriptase/ribonuclease H;
DE              EC=2.7.7.49;
DE              EC=2.7.7.7;
DE              EC=3.1.26.13;
DE     AltName: Full=Exoribonuclease H;
DE              EC=3.1.13.2;
DE     AltName: Full=p66 RT;
DE   Contains:
DE     RecName: Full=p51 RT;
DE   Contains:
DE     RecName: Full=p15;
DE   Contains:
DE     RecName: Full=Integrase;
DE              Short=IN;
GN   Name=gag-pol;
OS   Human immunodeficiency virus type 1 group M subtype B (isolate BH10)
OS   (HIV-1).
OC   Viruses; Retro-transcribing viruses; Retroviridae; Orthoretrovirinae;
OC   Lentivirus; Primate lentivirus group.
OX   NCBI_TaxID=11678;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=2578615; DOI=10.1038/313277a0;
RA   Ratner L., Haseltine W.A., Patarca R., Livak K.J., Starcich B.R.,
RA   Josephs S.F., Doran E.R., Rafalski J.A., Whitehorn E.A.,
RA   Baumeister K., Ivanoff L., Petteway S.R. Jr., Pearson M.L.,
RA   Lautenberger J.A., Papas T.S., Ghrayeb J., Chang N.T., Gallo R.C.,
RA   Wong-Staal F.;
RT   "Complete nucleotide sequence of the AIDS virus, HTLV-III.";
RL   Nature 313:277-284(1985).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=Isolate PV22;
RX   PubMed=2982104; DOI=10.1038/313450a0;
RA   Muesing M.A., Smith D.H., Cabradilla C.D., Benton C.V., Lasky L.A.,
RA   Capon D.J.;
RT   "Nucleic acid structure and expression of the human
RT   AIDS/lymphadenopathy retrovirus.";
RL   Nature 313:450-458(1985).
RN   [3]
RP   SEQUENCE REVISION.
RA   Muesing M.A.;
RL   Submitted (MAY-1992) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   CHARACTERIZATION OF RNASE H.
RX   PubMed=1722202;
RA   DeStefano J.J., Buiser R.G., Mallaber L.M., Bambara R.A., Fay P.J.;
RT   "Human immunodeficiency virus reverse transcriptase displays a
RT   partially processive 3' to 5' endonuclease activity.";
RL   J. Biol. Chem. 266:24295-24301(1991).
RN   [5]
RP   PROTEOLYTIC PROCESSING OF POLYPROTEIN, AND MUTAGENESIS OF PHE-1039 AND
RP   LEU-1159.
RX   PubMed=2044756; DOI=10.1016/0014-5793(91)80583-O;
RA   Jupp R.A., Phylip L.H., Mills J.S., Le Grice S.F.J., Kay J.;
RT   "Mutating P2 and P1 residues at cleavage junctions in the HIV-1 pol
RT   polyprotein. Effects on hydrolysis by HIV-1 proteinase.";
RL   FEBS Lett. 283:180-184(1991).
RN   [6]
RP   MUTAGENESIS OF HIS-1138.
RX   PubMed=1714505; DOI=10.1016/0022-2836(91)90119-Q;
RA   Wohrl B.M., Volkmann S., Moelling K.;
RT   "Mutations of a conserved residue within HIV-1 ribonuclease H affect
RT   its exo- and endonuclease activities.";
RL   J. Mol. Biol. 220:801-818(1991).
RN   [7]
RP   ACTIVE SITES OF REVERSE TRANSCRIPTASE, AND MUTAGENESIS OF ASP-709;
RP   ASP-784 AND ASP-785.
RX   PubMed=8794733; DOI=10.1021/bi960364x;
RA   Kaushik N., Rege N., Yadav P.N.S., Sarafianos S.G., Modak M.J.,
RA   Pandey V.N.;
RT   "Biochemical analysis of catalytically crucial aspartate mutants of
RT   human immunodeficiency virus type 1 reverse transcriptase.";
RL   Biochemistry 35:11536-11546(1996).
RN   [8]
RP   MUTAGENESIS OF GLU-823; PRO-824; PRO-825; PHE-826; LEU-827; TRP-828;
RP   MET-829; GLY-830; TYR-831; GLU-832 AND HIS-834.
RX   PubMed=9111014; DOI=10.1074/jbc.272.17.11157;
RA   Palaniappan C., Wisniewski M., Jacques P.S., Le Grice S.F., Fay P.J.,
RA   Bambara R.A.;
RT   "Mutations within the primer grip region of HIV-1 reverse
RT   transcriptase result in loss of RNase H function.";
RL   J. Biol. Chem. 272:11157-11164(1997).
RN   [9]
RP   MUTAGENESIS OF PRO-651; PRO-654; LEU-673; SER-755; PRO-756; MET-783;
RP   ILE-856; GLY-861; LEU-863; TRP-865; LEU-878; ALA-898; LEU-902; LEU-909
RP   AND GLU-1077.
RX   PubMed=9533880; DOI=10.1006/jmbi.1998.1624;
RA   Gao H.-Q., Boyer P.L., Arnold E., Hughes S.H.;
RT   "Effects of mutations in the polymerase domain on the polymerase,
RT   RNase H and strand transfer activities of human immunodeficiency virus
RT   type 1 reverse transcriptase.";
RL   J. Mol. Biol. 277:559-572(1998).
RN   [10]
RP   MUTAGENESIS OF TYR-782; MET-783; ASP-784 AND ASP-785.
RX   PubMed=9657675; DOI=10.1021/bi980549z;
RA   Harris D., Yadav P.N.S., Pandey V.N.;
RT   "Loss of polymerase activity due to Tyr to Phe substitution in the
RT   YMDD motif of human immunodeficiency virus type-1 reverse
RT   transcriptase is compensated by Met to Val substitution within the
RT   same motif.";
RL   Biochemistry 37:9630-9640(1998).
RN   [11]
RP   FUNCTION OF RNASE H.
RX   PubMed=9658129;
RA   Smith C.M., Leon O., Smith J.S., Roth M.J.;
RT   "Sequence requirements for removal of tRNA by an isolated human
RT   immunodeficiency virus type 1 RNase H domain.";
RL   J. Virol. 72:6805-6812(1998).
RN   [12]
RP   MUTAGENESIS OF LYS-664.
RX   PubMed=10794716; DOI=10.1042/0264-6021:3480077;
RA   Sluis-Cremer N., Arion D., Kaushik N., Lim H., Parniak M.A.;
RT   "Mutational analysis of Lys65 of HIV-1 reverse transcriptase.";
RL   Biochem. J. 348:77-82(2000).
RN   [13]
RP   CHARACTERIZATION OF RNASE H.
RX   PubMed=11035788; DOI=10.1073/pnas.210392297;
RA   Wisniewski M., Balakrishnan M., Palaniappan C., Fay P.J.,
RA   Bambara R.A.;
RT   "Unique progressive cleavage mechanism of HIV reverse transcriptase
RT   RNase H.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:11978-11983(2000).
RN   [14]
RP   RIBOSOMAL FRAMESHIFT, PROTEOLYTIC PROCESSING OF POLYPROTEIN, AND
RP   MUTAGENESIS OF PHE-440 AND PHE-500.
RX   PubMed=11172099;
RA   Chen N., Morag A., Almog N., Blumenzweig I., Dreazin O., Kotler M.;
RT   "Extended nucleocapsid protein is cleaved from the Gag-Pol precursor
RT   of human immunodeficiency virus type 1.";
RL   J. Gen. Virol. 82:581-590(2001).
RN   [15]
RP   GAG/GAG-POL RATIO.
RX   PubMed=11160682; DOI=10.1128/JVI.75.4.1834-1841.2001;
RA   Shehu-Xhilaga M., Crowe S.M., Mak J.;
RT   "Maintenance of the Gag/Gag-Pol ratio is important for human
RT   immunodeficiency virus type 1 RNA dimerization and viral
RT   infectivity.";
RL   J. Virol. 75:1834-1841(2001).
RN   [16]
RP   ACTIVE SITE OF PROTEASE.
RX   PubMed=12924029;
RA   Koval'skii D.B., Kanibolotskii D.S., Dubina V.N., Korneliuk A.I.;
RT   "Conformational changes in HIV-1 proteinase: effect of protonation of
RT   the active center on conformation of HIV-1 proteinase in water.";
RL   Ukr. Biokhim. Zh. 74:135-138(2002).
RN   [17]
RP   MUTAGENESIS OF TRP-752; ILE-766; LEU-786 AND VAL-788.
RX   PubMed=12501197; DOI=10.1021/bi026311z;
RA   Sharma B., Kaushik N., Singh K., Kumar S., Pandey V.N.;
RT   "Substitution of conserved hydrophobic residues in motifs B and C of
RT   HIV-1 RT alters the geometry of its catalytic pocket.";
RL   Biochemistry 41:15685-15697(2002).
RN   [18]
RP   MUTAGENESIS OF TYR-1100.
RX   PubMed=11684697; DOI=10.1074/jbc.M110254200;
RA   Arion D., Sluis-Cremer N., Min K.-L., Abram M.E., Fletcher R.S.,
RA   Parniak M.A.;
RT   "Mutational analysis of Tyr-501 of HIV-1 reverse transcriptase.
RT   Effects on ribonuclease H activity and inhibition of this activity by
RT   N-acylhydrazones.";
RL   J. Biol. Chem. 277:1370-1374(2002).
RN   [19]
RP   DOMAIN TRYPTOPHAN REPEAT MOTIF, AND MUTAGENESIS OF TRP-997; TRP-1000;
RP   TRP-1001; TYR-1004; TRP-1005; TRP-1009 AND TRP-1013.
RX   PubMed=12559908; DOI=10.1016/S0022-2836(02)01433-X;
RA   Tachedjian G., Aronson H.-E., de los Santos M., Seehra J., McCoy J.M.,
RA   Goff S.P.;
RT   "Role of residues in the tryptophan repeat motif for HIV-1 reverse
RT   transcriptase dimerization.";
RL   J. Mol. Biol. 326:381-396(2003).
RN   [20]
RP   CHARACTERIZATION OF RNASE H.
RX   PubMed=15533434; DOI=10.1016/j.jmb.2004.09.081;
RA   Schultz S.J., Zhang M., Champoux J.J.;
RT   "Recognition of internal cleavage sites by retroviral RNases H.";
RL   J. Mol. Biol. 344:635-652(2004).
RN   [21]
RP   CHARACTERIZATION OF REVERSE TRANSCRIPTASE, AND MUTAGENESIS OF
RP   TRP-1000.
RX   PubMed=15852304; DOI=10.1002/prot.20480;
RA   Tachedjian G., Radzio J., Sluis-Cremer N.;
RT   "Relationship between enzyme activity and dimeric structure of
RT   recombinant HIV-1 reverse transcriptase.";
RL   Proteins 60:5-13(2005).
RN   [22]
RP   CHARACTERIZATION OF RNASE H.
RX   PubMed=16141194; DOI=10.1093/nar/gki779;
RA   Mulder B.A., Anaya S., Yu P., Lee K.W., Nguyen A., Murphy J.,
RA   Willson R., Briggs J.M., Gao X., Hardin S.H.;
RT   "Nucleotide modification at the gamma-phosphate leads to the improved
RT   fidelity of HIV-1 reverse transcriptase.";
RL   Nucleic Acids Res. 33:4865-4873(2005).
RN   [23]
RP   MUTAGENESIS OF ALA-1036; GLU-1037; THR-1038; PHE-1039; TYR-1040 AND
RP   VAL-1041.
RX   PubMed=16140771; DOI=10.1128/JVI.79.18.11952-11961.2005;
RA   Abram M.E., Parniak M.A.;
RT   "Virion instability of human immunodeficiency virus type 1 reverse
RT   transcriptase (RT) mutated in the protease cleavage site between RT
RT   p51 and the RT RNase H domain.";
RL   J. Virol. 79:11952-11961(2005).
RN   [24]
RP   METHYLATION AT ARG-387 AND ARG-409 BY HUMAN PRMT6, AND INTERACTION
RP   WITH HUMAN PRMT6.
RX   PubMed=17415034; DOI=10.1097/QAD.0b013e32803277ae;
RA   Invernizzi C.F., Xie B., Frankel F.A., Feldhammer M., Roy B.B.,
RA   Richard S., Wainberg M.A.;
RT   "Arginine methylation of the HIV-1 nucleocapsid protein results in its
RT   diminished function.";
RL   AIDS 21:795-805(2007).
RN   [25]
RP   REVIEW.
RX   PubMed=8791726;
RA   Vogt V.M.;
RT   "Proteolytic processing and particle maturation.";
RL   Curr. Top. Microbiol. Immunol. 214:95-131(1996).
RN   [26]
RP   REVIEW.
RX   PubMed=9878383; DOI=10.1006/jmbi.1998.2354;
RA   Turner B.G., Summers M.F.;
RT   "Structural biology of HIV.";
RL   J. Mol. Biol. 285:1-32(1999).
RN   [27]
RP   REVIEW.
RX   PubMed=11700285; DOI=10.1146/annurev.genet.35.102401.090551;
RA   Negroni M., Buc H.;
RT   "Mechanisms of retroviral recombination.";
RL   Annu. Rev. Genet. 35:275-302(2001).
RN   [28]
RP   REVIEW.
RX   PubMed=11983066; DOI=10.1186/gb-2002-3-4-reviews3006;
RA   Dunn B.M., Goodenow M.M., Gustchina A., Wlodawer A.;
RT   "Retroviral proteases.";
RL   Genome Biol. 3:REVIEWS3006.1-REVIEWS3006.7(2002).
RN   [29]
RP   REVIEW.
RX   PubMed=12873766; DOI=10.1016/S0005-2736(03)00163-9;
RA   Scarlata S., Carter C.;
RT   "Role of HIV-1 Gag domains in viral assembly.";
RL   Biochim. Biophys. Acta 1614:62-72(2003).
RN   [30]
RP   3D-STRUCTURE MODELING OF PROTEASE DOMAIN.
RX   PubMed=2537531; DOI=10.1126/science.2537531;
RA   Weber I.T., Miller M., Jaskolski M., Leis J., Skalka A.M.,
RA   Wlodawer A.;
RT   "Molecular modeling of the HIV-1 protease and its substrate binding
RT   site.";
RL   Science 243:928-931(1989).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) OF 600-1159.
RX   PubMed=2476069; DOI=10.1016/0003-9861(89)90493-1;
RA   Mizrahi V., Lazarus G.M., Miles L.M., Meyers C.A., Debouck C.;
RT   "Recombinant HIV-1 reverse transcriptase: purification, primary
RT   structure, and polymerase/ribonuclease H activities.";
RL   Arch. Biochem. Biophys. 273:347-358(1989).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 501-599 IN COMPLEX WITH A C2
RP   SYMMETRIC INHIBITOR.
RX   PubMed=2200122; DOI=10.1126/science.2200122;
RA   Erickson J., Neidhart D.J., Vandrie J., Kempf D.J., Wang X.C.,
RA   Norbeck D.W., Plattner J.J., Rittenhouse J.W., Turon M.,
RA   Wideburg N.E., Kohlbrenner W.E., Simmer R., Helfrich R., Paul D.A.,
RA   Knigge M.;
RT   "Design, activity, and 2.8 A crystal structure of a C2 symmetric
RT   inhibitor complexed to HIV-1 protease.";
RL   Science 249:527-533(1990).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 1026-1161.
RX   PubMed=1707186; DOI=10.1126/science.1707186;
RA   Davies J.F. II, Hostomska Z., Hostomsky Z., Jordan S.R.,
RA   Matthews D.A.;
RT   "Crystal structure of the ribonuclease H domain of HIV-1 reverse
RT   transcriptase.";
RL   Science 252:88-95(1991).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 1026-1159.
RX   PubMed=1718968;
RA   Evans D.B., Brawn K., Deibel M.R. Jr., Tarpley W.G., Sharma S.K.;
RT   "A recombinant ribonuclease H domain of HIV-1 reverse transcriptase
RT   that is enzymatically active.";
RL   J. Biol. Chem. 266:20583-20585(1991).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 1026-1161.
RX   PubMed=1713588;
RA   Hostomska Z., Matthews D.A., Davies J.F. II, Nodes B.R., Hostomsky Z.;
RT   "Proteolytic release and crystallization of the RNase H domain of
RT   human immunodeficiency virus type 1 reverse transcriptase.";
RL   J. Biol. Chem. 266:14697-14702(1991).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (3.5 ANGSTROMS) OF 600-1155 IN COMPLEX WITH AN
RP   INHIBITOR.
RX   PubMed=1377403; DOI=10.1126/science.1377403;
RA   Kohlstaedt L.A., Wang J., Friedman J.M., Rice P.A., Steitz T.A.;
RT   "Crystal structure at 3.5-A resolution of HIV-1 reverse transcriptase
RT   complexed with an inhibitor.";
RL   Science 256:1783-1790(1992).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 600-1157.
RX   PubMed=1374166; DOI=10.1038/357085a0;
RA   Arnold E., Jacobo-Molina A., Nanni R.G., Williams R.L., Lu X.,
RA   Ding J., Clark A.D. Jr., Zhang A., Ferris A.L., Clark P., Hizi A.,
RA   Hughes S.H.;
RT   "Structure of HIV-1 reverse transcriptase/DNA complex at 7 A
RT   resolution showing active site locations.";
RL   Nature 357:85-89(1992).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 501-599.
RX   PubMed=8230097; DOI=10.1021/jm00073a010;
RA   Wonacott A., Cooke R., Hayes F.R., Hann M.M., Jhoti H., McMeekin P.,
RA   Mistry A., Murray-Rust P., Singh O.M., Weir M.P.;
RT   "A series of penicillin-derived C2-symmetric inhibitors of HIV-1
RT   proteinase: structural and modeling studies.";
RL   J. Med. Chem. 36:3113-3119(1993).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 501-599 IN COMPLEX WITH A
RP   NOVEL GAMMA-TURN MIMETIC INHIBITOR.
RX   PubMed=8360876; DOI=10.1021/jm00068a008;
RA   Newlander K.A., Callahan J.F., Moore M.L., Tomaszek T.A. Jr.,
RA   Huffman W.F.;
RT   "A novel constrained reduced-amide inhibitor of HIV-1 protease derived
RT   from the sequential incorporation of gamma-turn mimetics into a model
RT   substrate.";
RL   J. Med. Chem. 36:2321-2331(1993).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 600-1155.
RX   PubMed=7687065; DOI=10.1073/pnas.90.13.6320;
RA   Jacobo-Molina A., Ding J., Nanni R.G., Clark A.D. Jr., Lu X.,
RA   Tantillo C., Williams R.L., Kamer G., Ferris A.L., Clark P., Hizi A.,
RA   Hughes S.H., Arnold E.;
RT   "Crystal structure of human immunodeficiency virus type 1 reverse
RT   transcriptase complexed with double-stranded DNA at 3.0-A resolution
RT   shows bent DNA.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:6320-6324(1993).
RN   [41]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 600-1159.
RX   PubMed=7513427; DOI=10.1073/pnas.91.9.3911;
RA   Smerdon S.J., Jager J., Wang J., Kohlstaedt L.A., Chirino A.J.,
RA   Friedman J.M., Rice P.A., Steitz T.A.;
RT   "Structure of the binding site for nonnucleoside inhibitors of the
RT   reverse transcriptase of human immunodeficiency virus type 1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:3911-3915(1994).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 501-599 IN COMPLEX WITH A
RP   NOVEL PSEUDOSYMMETRIC INHIBITOR.
RX   PubMed=7613867; DOI=10.1016/S0969-2126(01)00169-1;
RA   Priestle J.P., Fassler A., Rosel J., Tintelnot-Blomley M., Strop P.,
RA   Gruetter M.G.;
RT   "Comparative analysis of the X-ray structures of HIV-1 and HIV-2
RT   proteases in complex with CGP 53820, a novel pseudosymmetric
RT   inhibitor.";
RL   Structure 3:381-389(1995).
RN   [43]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 600-1155 IN COMPLEX WITH A
RP   NONNUCLEOSIDE INHIBITOR.
RX   PubMed=7545077; DOI=10.1038/nsb0595-407;
RA   Ding J., Das K., Moereels H., Koymans L., Andries K., Janssen P.A.,
RA   Hughes S.H., Arnold E.;
RT   "Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the
RT   binding of diverse nonnucleoside inhibitors.";
RL   Nat. Struct. Biol. 2:407-415(1995).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 600-1157 IN COMPLEX WITH A
RP   NON-NUCLEOSIDE INHIBITOR.
RX   PubMed=7542140; DOI=10.1016/S0969-2126(01)00168-X;
RA   Ding J., Das K., Tantillo C., Zhang W., Clark A.D. Jr., Jessen S.,
RA   Lu X., Hsiou Y., Jacobo-Molina A., Andries K., Et A.L.;
RT   "Structure of HIV-1 reverse transcriptase in a complex with the non-
RT   nucleoside inhibitor alpha-APA R 95845 at 2.8-A resolution.";
RL   Structure 3:365-379(1995).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) OF 600-1159.
RX   PubMed=7532306; DOI=10.1073/pnas.92.4.1222;
RA   Rodgers D.W., Gamblin S.J., Harris B.A., Ray S., Culp J.S.,
RA   Hellmig B., Woolf D.J., Debouck C., Harrison S.C.;
RT   "The structure of unliganded reverse transcriptase from the human
RT   immunodeficiency virus type 1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:1222-1226(1995).
RN   [46]
RP   STRUCTURE BY NMR OF 1379-1429.
RX   PubMed=7552753; DOI=10.1038/nsb0995-807;
RA   Eijkelenboom A.P.A.M., Lutzke R.A., Boelens R., Plasterk R.H.A.,
RA   Kaptein R., Hard K.;
RT   "The DNA-binding domain of HIV-1 integrase has an SH3-like fold.";
RL   Nat. Struct. Biol. 2:807-810(1995).
RN   [47]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 501-599 IN COMPLEX WITH THE
RP   PEPTIDIC INHIBITOR U-89360E.
RX   PubMed=7827064; DOI=10.1021/bi00004a007;
RA   Lin Y.Z., Lin X.L., Hong L., Foundling S.I., Heinrikson R.L.,
RA   Thaisrivongs S., Leelamanit W., Raterman D., Shah M., Dunn B.M.,
RA   Tang J.;
RT   "Effect of point mutations on the kinetics and the inhibition of human
RT   immunodeficiency virus type 1 protease: relationship to drug
RT   resistance.";
RL   Biochemistry 34:1143-1152(1995).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 600-1155.
RX   PubMed=8805568; DOI=10.1016/S0969-2126(96)00091-3;
RA   Hsiou Y., Ding J., Das K., Clark A.D. Jr., Hughes S.H., Arnold E.;
RT   "Structure of unliganded HIV-1 reverse transcriptase at 2.7-A
RT   resolution: implications of conformational changes for polymerization
RT   and inhibition mechanisms.";
RL   Structure 4:853-860(1996).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 501-599 IN COMPLEX WITH A
RP   SULFAMIDE AND A UREA DERIVATIVE.
RX   PubMed=9083478; DOI=10.1021/jm960588d;
RA   Backbro K., Lowgren S., Osterlund K., Atepo J., Unge T., Hulten J.,
RA   Bonham N.M., Schaal W., Karlen A., Hallberg A.;
RT   "Unexpected binding mode of a cyclic sulfamide HIV-1 protease
RT   inhibitor.";
RL   J. Med. Chem. 40:898-902(1997).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 502-599 IN COMPLEX WITH A
RP   CYCLIC UREA INHIBITOR.
RX   PubMed=9048541; DOI=10.1021/bi962234u;
RA   Ala P.J., Huston E.E., Klabe R.M., McCabe D.D., Duke J.L., Rizzo C.J.,
RA   Korant B.D., DeLoskey R.J., Lam P.Y.S., Hodge C.N., Chang C.-H.;
RT   "Molecular basis of HIV-1 protease drug resistance: structural
RT   analysis of mutant proteases complexed with cyclic urea inhibitors.";
RL   Biochemistry 36:1573-1580(1997).
RN   [51]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 501-599 IN COMPLEX WITH THE
RP   PEPTIDIC INHIBITOR U-89360E.
RX   PubMed=9450540; DOI=10.1016/S0014-5793(97)01477-4;
RA   Hong L., Zhang X.-J., Foundling S.I., Hartsuck J.A., Tang J.;
RT   "Structure of a G48H mutant of HIV-1 protease explains how glycine-48
RT   replacements produce mutants resistant to inhibitor drugs.";
RL   FEBS Lett. 420:11-16(1997).
RN   [52]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 501-599.
RX   PubMed=9258349; DOI=10.1021/jm970195u;
RA   Smith A.B. III, Hirschmann R., Pasternak A., Yao W., Sprengeler P.A.,
RA   Holloway M.K., Kuo L.C., Chen Z., Darke P.L., Schleif W.A.;
RT   "An orally bioavailable pyrrolinone inhibitor of HIV-1 protease:
RT   computational analysis and X-ray crystal structure of the enzyme
RT   complex.";
RL   J. Med. Chem. 40:2440-2444(1997).
RN   [53]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 501-599 IN COMPLEX WITH A
RP   PEPTIDIC INHIBITOR.
RX   PubMed=9521105; DOI=10.1002/pro.5560070209;
RA   Hong L., Hartsuck J.A., Foundling S.I., Ermolieff J., Tang J.;
RT   "Active-site mobility in human immunodeficiency virus, type 1,
RT   protease as demonstrated by crystal structure of A28S mutant.";
RL   Protein Sci. 7:300-305(1998).
RN   [54]
RP   X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) OF 588-1027.
RX   PubMed=9831551; DOI=10.1126/science.282.5394.1669;
RA   Huang H., Chopra R., Verdine G.L., Harrison S.C.;
RT   "Structure of a covalently trapped catalytic complex of HIV-1 reverse
RT   transcriptase: implications for drug resistance.";
RL   Science 282:1669-1675(1998).
RN   [55]
RP   X-RAY CRYSTALLOGRAPHY (4.75 ANGSTROMS) OF 600-1153 IN COMPLEX WITH AN
RP   RNA PSEUDOKNOT INHIBITOR.
RX   PubMed=9687519; DOI=10.1093/emboj/17.15.4535;
RA   Jaeger J., Restle T., Steitz T.A.;
RT   "The structure of HIV-1 reverse transcriptase complexed with an RNA
RT   pseudoknot inhibitor.";
RL   EMBO J. 17:4535-4542(1998).
RN   [56]
RP   X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF 600-1155 IN COMPLEX WITH A
RP   NON-NUCLEOSIDE INHIBITOR.
RX   PubMed=9813120; DOI=10.1006/jmbi.1998.2171;
RA   Hsiou Y., Das K., Ding J., Clark A.D. Jr., Kleim J.P., Rosner M.,
RA   Winkler I., Riess G., Hughes S.H., Arnold E.;
RT   "Structures of Tyr188Leu mutant and wild-type HIV-1 reverse
RT   transcriptase complexed with the non-nucleoside inhibitor HBY 097:
RT   inhibitor flexibility is a useful design feature for reducing drug
RT   resistance.";
RL   J. Mol. Biol. 284:313-323(1998).
RN   [57]
RP   X-RAY CRYSTALLOGRAPHY (3.5 ANGSTROMS) OF 600-1157.
RX   PubMed=10468556; DOI=10.1073/pnas.96.18.10027;
RA   Sarafianos S.G., Das K., Clark A.D. Jr., Ding J., Boyer P.L.,
RA   Hughes S.H., Arnold E.;
RT   "Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves
RT   steric hindrance with beta-branched amino acids.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:10027-10032(1999).
RN   [58]
RP   X-RAY CRYSTALLOGRAPHY (2.73 ANGSTROMS) OF 600-1156.
RX   PubMed=10650066; DOI=10.1021/jm990572y;
RA   Hogberg M., Sahlberg C., Engelhardt P., Noreen R., Kangasmetsa J.,
RA   Johansson N.G., Oberg B., Vrang L., Zhang H., Sahlberg B.L., Unge T.,
RA   Lovgren S., Fridborg K., Backbro K.;
RT   "Urea-PETT compounds as a new class of HIV-1 reverse transcriptase
RT   inhibitors. 3. Synthesis and further structure-activity relationship
RT   studies of PETT analogues.";
RL   J. Med. Chem. 43:304-304(2000).
RN   [59]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 600-1152 IN COMPLEX WITH AN
RP   OLIGONUCLEOTIDE, AND ACTIVE SITES OF RNASE H.
RX   PubMed=11250910; DOI=10.1093/emboj/20.6.1449;
RA   Sarafianos S.G., Das K., Tantillo C., Clark A.D. Jr., Ding J.,
RA   Whitcomb J.M., Boyer P.L., Hughes S.H., Arnold E.;
RT   "Crystal structure of HIV-1 reverse transcriptase in complex with a
RT   polypurine tract RNA:DNA.";
RL   EMBO J. 20:1449-1461(2001).
RN   [60]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 600-1159.
RX   PubMed=11371163; DOI=10.1006/jmbi.2001.4648;
RA   Hsiou Y., Ding J., Das K., Clark A.D. Jr., Boyer P.L., Lewi P.,
RA   Janssen P.A., Kleim J.P., Rosner M., Hughes S.H., Arnold E.;
RT   "The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug
RT   resistance.";
RL   J. Mol. Biol. 309:437-445(2001).
RN   [61]
RP   X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF 600-1157.
RX   PubMed=12456667; DOI=10.1093/emboj/cdf637;
RA   Sarafianos S.G., Clark A.D. Jr., Das K., Tuske S., Birktoft J.J.,
RA   Ilankumaran P., Ramesha A.R., Sayer J.M., Jerina D.M., Boyer P.L.,
RA   Hughes S.H., Arnold E.;
RT   "Structures of HIV-1 reverse transcriptase with pre- and post-
RT   translocation AZTMP-terminated DNA.";
RL   EMBO J. 21:6614-6624(2002).
RN   [62]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 600-1159 IN COMPLEX WITH
RP   EFIVARENZ.
RX   PubMed=11895437; DOI=10.1046/j.1432-1327.2002.02811.x;
RA   Lindberg J., Sigurdsson S., Lowgren S., Andersson H.O., Sahlberg C.,
RA   Noreen R., Fridborg K., Zhang H., Unge T.;
RT   "Structural basis for the inhibitory efficacy of efavirenz (DMP-266),
RT   MSC194 and PNU142721 towards the HIV-1 RT K103N mutant.";
RL   Eur. J. Biochem. 269:1670-1677(2002).
RN   [63]
RP   X-RAY CRYSTALLOGRAPHY (1.81 ANGSTROMS) OF 501-599.
RX   PubMed=12694187; DOI=10.1046/j.1432-1033.2003.03533.x;
RA   Andersson H.O., Fridborg K., Lowgren S., Alterman M., Muhlman A.,
RA   Bjorsne M., Garg N., Kvarnstrom I., Schaal W., Classon B., Karlen A.,
RA   Danielsson U.H., Ahlsen G., Nillroth U., Vrang L., Oberg B.,
RA   Samuelsson B., Hallberg A., Unge T.;
RT   "Optimization of P1-P3 groups in symmetric and asymmetric HIV-1
RT   protease inhibitors.";
RL   Eur. J. Biochem. 270:1746-1758(2003).
RN   [64]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 501-599 IN COMPLEX WITH
RP   MONOPYRROLINONE-BASED INHIBITORS LDC271 AND LGZ479.
RX   PubMed=12723947; DOI=10.1021/jm0204587;
RA   Smith A.B. III, Cantin L.D., Pasternak A., Guise-Zawacki L., Yao W.,
RA   Charnley A.K., Barbosa J., Sprengeler P.A., Hirschmann R., Munshi S.,
RA   Olsen D.B., Schleif W.A., Kuo L.C.;
RT   "Design, synthesis, and biological evaluation of monopyrrolinone-based
RT   HIV-1 protease inhibitors.";
RL   J. Med. Chem. 46:1831-1844(2003).
RN   [65]
RP   X-RAY CRYSTALLOGRAPHY (1.79 ANGSTROMS) OF 501-599.
RX   PubMed=15560801; DOI=10.1111/j.1432-1033.2004.04431.x;
RA   Lindberg J., Pyring D., Lowgren S., Rosenquist A., Zuccarello G.,
RA   Kvarnstrom I., Zhang H., Vrang L., Classon B., Hallberg A.,
RA   Samuelsson B., Unge T.;
RT   "Symmetric fluoro-substituted diol-based HIV protease inhibitors.
RT   Ortho-fluorinated and meta-fluorinated P1/P1'-benzyloxy side groups
RT   significantly improve the antiviral activity and preserve binding
RT   efficacy.";
RL   Eur. J. Biochem. 271:4594-4602(2004).
RN   [66]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 600-1157.
RX   PubMed=15016861; DOI=10.1128/JVI.78.7.3387-3397.2004;
RA   Peletskaya E.N., Kogon A.A., Tuske S., Arnold E., Hughes S.H.;
RT   "Nonnucleoside inhibitor binding affects the interactions of the
RT   fingers subdomain of human immunodeficiency virus type 1 reverse
RT   transcriptase with DNA.";
RL   J. Virol. 78:3387-3397(2004).
RN   [67]
RP   X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF 600-1157 IN COMPLEX WITH DNA
RP   BOUND TO TENOFOVIR.
RX   PubMed=15107837; DOI=10.1038/nsmb760;
RA   Tuske S., Sarafianos S.G., Clark A.D. Jr., Ding J., Naeger L.K.,
RA   White K.L., Miller M.D., Gibbs C.S., Boyer P.L., Clark P., Wang G.,
RA   Gaffney B.L., Jones R.A., Jerina D.M., Hughes S.H., Arnold E.;
RT   "Structures of HIV-1 RT-DNA complexes before and after incorporation
RT   of the anti-AIDS drug tenofovir.";
RL   Nat. Struct. Mol. Biol. 11:469-474(2004).
RN   [68]
RP   X-RAY CRYSTALLOGRAPHY (1.3 ANGSTROMS) OF 501-599 IN COMPLEX WITH
RP   ARYLSULFONAMIDE AZACYCLIC UREA INHIBITORS.
RX   PubMed=15225729; DOI=10.1016/j.bmcl.2004.05.036;
RA   Huang P.P., Randolph J.T., Klein L.L., Vasavanonda S., Dekhtyar T.,
RA   Stoll V.S., Kempf D.J.;
RT   "Synthesis and antiviral activity of P1' arylsulfonamide azacyclic
RT   urea HIV protease inhibitors.";
RL   Bioorg. Med. Chem. Lett. 14:4075-4078(2004).
RN   [69]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 501-599 IN COMPLEX WITH
RP   OXIMINOARYLSULFONAMIDE INHIBITOR.
RX   PubMed=15837308; DOI=10.1016/j.bmcl.2005.03.008;
RA   Yeung C.M., Klein L.L., Flentge C.A., Randolph J.T., Zhao C., Sun M.,
RA   Dekhtyar T., Stoll V.S., Kempf D.J.;
RT   "Oximinoarylsulfonamides as potent HIV protease inhibitors.";
RL   Bioorg. Med. Chem. Lett. 15:2275-2278(2005).
CC   -!- FUNCTION: Gag-Pol polyprotein: Mediates, with Gag polyrotein, the
CC       essential events in virion assembly, including binding the plasma
CC       membrane, making the protein-protein interactions necessary to
CC       create spherical particles, recruiting the viral Env proteins, and
CC       packaging the genomic RNA via direct interactions with the RNA
CC       packaging sequence (Psi). Gag-Pol polyprotein may regulate its own
CC       translation, by the binding genomic RNA in the 5'-UTR. At low
CC       concentration, the polyprotein would promote translation, whereas
CC       at high concentration, the polyprotein would encapsidate genomic
CC       RNA and then shutt off translation. {ECO:0000250}.
CC   -!- FUNCTION: Matrix protein p17: Targets the polyprotein to the
CC       plasma membrane via a multipartite membrane-binding signal, that
CC       includes its myristoylated N-terminus. Matrix protein is part of
CC       the pre-integration complex. Implicated in the release from host
CC       cell mediated by Vpu. Binds to RNA.
CC       {ECO:0000250|UniProtKB:P12497}.
CC   -!- FUNCTION: Capsid protein p24: Forms the conical core that
CC       encapsulates the genomic RNA-nucleocapsid complex in the virion.
CC       Most core are conical, with only 7% tubular. The core is
CC       constituted by capsid protein hexamer subunits. The core is
CC       disassembled soon after virion entry (By similarity). Host
CC       restriction factors such as TRIM5-alpha or TRIMCyp bind retroviral
CC       capsids and cause premature capsid disassembly, leading to blocks
CC       in reverse transcription. Capsid restriction by TRIM5 is one of
CC       the factors which restricts HIV-1 to the human species. Host PIN1
CC       apparently facilitates the virion uncoating. On the other hand,
CC       interactions with PDZD8 or CYPA stabilize the capsid.
CC       {ECO:0000250|UniProtKB:P04585, ECO:0000250|UniProtKB:P12497}.
CC   -!- FUNCTION: Nucleocapsid protein p7: Encapsulates and protects viral
CC       dimeric unspliced genomic RNA (gRNA). Binds these RNAs through its
CC       zinc fingers. Acts as a nucleic acid chaperone which is involved
CC       in rearangement of nucleic acid secondary structure during gRNA
CC       retrotranscription. Also facilitates template switch leading to
CC       recombination. As part of the polyprotein, participates to gRNA
CC       dimerization, packaging, tRNA incorporation and virion assembly.
CC       {ECO:0000250|UniProtKB:P04585}.
CC   -!- FUNCTION: Protease: Aspartyl protease that mediates proteolytic
CC       cleavages of Gag and Gag-Pol polyproteins during or shortly after
CC       the release of the virion from the plasma membrane. Cleavages take
CC       place as an ordered, step-wise cascade to yield mature proteins.
CC       This process is called maturation. Displays maximal activity
CC       during the budding process just prior to particle release from the
CC       cell. Also cleaves Nef and Vif, probably concomitantly with viral
CC       structural proteins on maturation of virus particles. Hydrolyzes
CC       host EIF4GI and PABP1 in order to shut off the capped cellular
CC       mRNA translation. The resulting inhibition of cellular protein
CC       synthesis serves to ensure maximal viral gene expression and to
CC       evade host immune response (By similarity).
CC       {ECO:0000250|UniProtKB:P04585, ECO:0000255|PROSITE-
CC       ProRule:PRU00275}.
CC   -!- FUNCTION: Reverse transcriptase/ribonuclease H: Multifunctional
CC       enzyme that converts the viral RNA genome into dsDNA in the
CC       cytoplasm, shortly after virus entry into the cell. This enzyme
CC       displays a DNA polymerase activity that can copy either DNA or RNA
CC       templates, and a ribonuclease H (RNase H) activity that cleaves
CC       the RNA strand of RNA-DNA heteroduplexes in a partially processive
CC       3' to 5' endonucleasic mode. Conversion of viral genomic RNA into
CC       dsDNA requires many steps. A tRNA(3)-Lys binds to the primer-
CC       binding site (PBS) situated at the 5'-end of the viral RNA. RT
CC       uses the 3' end of the tRNA primer to perform a short round of
CC       RNA-dependent minus-strand DNA synthesis. The reading proceeds
CC       through the U5 region and ends after the repeated (R) region which
CC       is present at both ends of viral RNA. The portion of the RNA-DNA
CC       heteroduplex is digested by the RNase H, resulting in a ssDNA
CC       product attached to the tRNA primer. This ssDNA/tRNA hybridizes
CC       with the identical R region situated at the 3' end of viral RNA.
CC       This template exchange, known as minus-strand DNA strong stop
CC       transfer, can be either intra- or intermolecular. RT uses the 3'
CC       end of this newly synthesized short ssDNA to perform the RNA-
CC       dependent minus-strand DNA synthesis of the whole template. RNase
CC       H digests the RNA template except for two polypurine tracts (PPTs)
CC       situated at the 5'-end and near the center of the genome. It is
CC       not clear if both polymerase and RNase H activities are
CC       simultaneous. RNase H probably can proceed both in a polymerase-
CC       dependent (RNA cut into small fragments by the same RT performing
CC       DNA synthesis) and a polymerase-independent mode (cleavage of
CC       remaining RNA fragments by free RTs). Secondly, RT performs DNA-
CC       directed plus-strand DNA synthesis using the PPTs that have not
CC       been removed by RNase H as primers. PPTs and tRNA primers are then
CC       removed by RNase H. The 3' and 5' ssDNA PBS regions hybridize to
CC       form a circular dsDNA intermediate. Strand displacement synthesis
CC       by RT to the PBS and PPT ends produces a blunt ended, linear dsDNA
CC       copy of the viral genome that includes long terminal repeats
CC       (LTRs) at both ends. {ECO:0000250|UniProtKB:P04585}.
CC   -!- FUNCTION: Integrase: Catalyzes viral DNA integration into the host
CC       chromosome, by performing a series of DNA cutting and joining
CC       reactions. This enzyme activity takes place after virion entry
CC       into a cell and reverse transcription of the RNA genome in dsDNA.
CC       The first step in the integration process is 3' processing. This
CC       step requires a complex comprising the viral genome, matrix
CC       protein, Vpr and integrase. This complex is called the pre-
CC       integration complex (PIC). The integrase protein removes 2
CC       nucleotides from each 3' end of the viral DNA, leaving recessed CA
CC       OH's at the 3' ends. In the second step, the PIC enters cell
CC       nucleus. This process is mediated through integrase and Vpr
CC       proteins, and allows the virus to infect a non dividing cell. This
CC       ability to enter the nucleus is specific of lentiviruses, other
CC       retroviruses cannot and rely on cell division to access cell
CC       chromosomes. In the third step, termed strand transfer, the
CC       integrase protein joins the previously processed 3' ends to the 5'
CC       ends of strands of target cellular DNA at the site of integration.
CC       The 5'-ends are produced by integrase-catalyzed staggered cuts, 5
CC       bp apart. A Y-shaped, gapped, recombination intermediate results,
CC       with the 5'-ends of the viral DNA strands and the 3' ends of
CC       target DNA strands remaining unjoined, flanking a gap of 5 bp. The
CC       last step is viral DNA integration into host chromosome. This
CC       involves host DNA repair synthesis in which the 5 bp gaps between
CC       the unjoined strands are filled in and then ligated. Since this
CC       process occurs at both cuts flanking the HIV genome, a 5 bp
CC       duplication of host DNA is produced at the ends of HIV-1
CC       integration. Alternatively, Integrase may catalyze the excision of
CC       viral DNA just after strand transfer, this is termed
CC       disintegration. {ECO:0000250|UniProtKB:P04585}.
CC   -!- CATALYTIC ACTIVITY: Specific for a P1 residue that is hydrophobic,
CC       and P1' variable, but often Pro. {ECO:0000255|PROSITE-
CC       ProRule:PRU00275}.
CC   -!- CATALYTIC ACTIVITY: Endohydrolysis of RNA in RNA/DNA hybrids.
CC       Three different cleavage modes: 1. sequence-specific internal
CC       cleavage of RNA. Human immunodeficiency virus type 1 and Moloney
CC       murine leukemia virus enzymes prefer to cleave the RNA strand one
CC       nucleotide away from the RNA-DNA junction. 2. RNA 5'-end directed
CC       cleavage 13-19 nucleotides from the RNA end. 3. DNA 3'-end
CC       directed cleavage 15-20 nucleotides away from the primer terminus.
CC       {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY: 3'-end directed exonucleolytic cleavage of
CC       viral RNA-DNA hybrid. {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY: Deoxynucleoside triphosphate + DNA(n) =
CC       diphosphate + DNA(n+1). {ECO:0000255|PROSITE-ProRule:PRU00405}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Note=Binds 2 magnesium ions for reverse transcriptase polymerase
CC       activity. {ECO:0000250};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Note=Binds 2 magnesium ions for ribonuclease H (RNase H) activity.
CC       Substrate-binding is a precondition for magnesium binding.
CC       {ECO:0000250};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Note=Magnesium ions are required for integrase activity. Binds at
CC       least 1, maybe 2 magnesium ions. {ECO:0000250};
CC   -!- ENZYME REGULATION: Protease: The viral protease is inhibited by
CC       many synthetic protease inhibitors (PIs), such as amprenavir,
CC       atazanavir, indinavir, loprinavir, nelfinavir, ritonavir and
CC       saquinavir. Use of protease inhibitors in tritherapy regimens
CC       permit more ambitious therapeutic strategies. Reverse
CC       transcriptase/ribonuclease H: RT can be inhibited either by
CC       nucleoside RT inhibitors (NRTIs) or by non nucleoside RT
CC       inhibitors (NNRTIs). NRTIs act as chain terminators, whereas
CC       NNRTIs inhibit DNA polymerization by binding a small hydrophobic
CC       pocket near the RT active site and inducing an allosteric change
CC       in this region. Classical NRTIs are abacavir, adefovir (PMEA),
CC       didanosine (ddI), lamivudine (3TC), stavudine (d4T), tenofovir
CC       (PMPA), zalcitabine (ddC), and zidovudine (AZT). Classical NNRTIs
CC       are atevirdine (BHAP U-87201E), delavirdine, efavirenz (DMP-266),
CC       emivirine (I-EBU), and nevirapine (BI-RG-587). The tritherapies
CC       used as a basic effective treatment of AIDS associate two NRTIs
CC       and one NNRTI. {ECO:0000250}.
CC   -!- SUBUNIT: Matrix protein p17: Homotrimer; further assembles as
CC       hexamers of trimers (By similarity). Matrix protein p17: Interacts
CC       with gp41 (via C-terminus) (By similarity). Matrix protein p17:
CC       interacts with host CALM1; this interaction induces a
CC       conformational change in the Matrix protein, triggering exposure
CC       of the myristate group (By similarity). Matrix protein p17:
CC       interacts with host AP3D1; this interaction allows the polyprotein
CC       trafficking to multivesicular bodies during virus assembly (By
CC       similarity). Matrix protein p17: Part of the pre-integration
CC       complex (PIC) which is composed of viral genome, matrix protein,
CC       Vpr and integrase (By similarity). Capsid protein p24: Homodimer;
CC       the homodimer further multimerizes as homohexamers or
CC       homopentamers. Capsid protein p24: Interacts with human PPIA/CYPA
CC       (By similarity); This interaction stabilizes the capsid. Capsid
CC       protein p24: Interacts with human NUP153 (By similarity). Capsid
CC       protein p24: Interacts with host PDZD8; this interaction
CC       stabilizes the capsid (By similarity). Capsid protein p24:
CC       Interacts with monkey TRIM5; this interaction destabilizes the
CC       capsid (By similarity).Protease: Homodimer, whose active site
CC       consists of two apposed aspartic acid residues. Reverse
CC       transcriptase/ribonuclease H: Heterodimer of p66 RT and p51 RT (RT
CC       p66/p51). Heterodimerization of RT is essential for DNA polymerase
CC       activity. Despite the sequence identities, p66 RT and p51 RT have
CC       distinct folding. Integrase: Homodimer; possibly can form
CC       homotetramer. Integrase: Part of the pre-integration complex (PIC)
CC       which is composed of viral genome, matrix protein, Vpr and
CC       integrase. Integrase: Interacts with human SMARCB1/INI1 and human
CC       PSIP1/LEDGF isoform 1. Integrase: Interacts with human KPNA3; this
CC       interaction might play a role in nuclear import of the pre-
CC       integration complex (By similarity). Integrase: Interacts with
CC       human NUP153; this interaction might play a role in nuclear import
CC       of the pre-integration complex (By similarity).
CC       {ECO:0000250|UniProtKB:P04585, ECO:0000250|UniProtKB:P12497}.
CC   -!- SUBCELLULAR LOCATION: Gag-Pol polyprotein: Host cell membrane;
CC       Lipid-anchor. Host endosome, host multivesicular body. Note=These
CC       locations are linked to virus assembly sites. The main location is
CC       the cell membrane, but under some circumstances, late endosomal
CC       compartments can serve as productive sites for virion assembly.
CC       {ECO:0000250|UniProtKB:P12497}.
CC   -!- SUBCELLULAR LOCATION: Matrix protein p17: Virion membrane; Lipid-
CC       anchor {ECO:0000305}. Host nucleus {ECO:0000250}. Host cytoplasm
CC       {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Capsid protein p24: Virion {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: Nucleocapsid protein p7: Virion
CC       {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: Reverse transcriptase/ribonuclease H: Virion
CC       {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: Integrase: Virion {ECO:0000305}. Host
CC       nucleus {ECO:0000305}. Host cytoplasm {ECO:0000305}. Note=Nuclear
CC       at initial phase, cytoplasmic at assembly. {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Ribosomal frameshifting; Named isoforms=2;
CC         Comment=Translation results in the formation of the Gag
CC         polyprotein most of the time. Ribosomal frameshifting at the
CC         gag-pol genes boundary occurs at low frequency and produces the
CC         Gag-Pol polyprotein. This strategy of translation probably
CC         allows the virus to modulate the quantity of each viral protein.
CC         Maintenance of a correct Gag to Gag-Pol ratio is essential for
CC         RNA dimerization and viral infectivity.
CC         {ECO:0000269|PubMed:11172099};
CC       Name=Gag-Pol polyprotein;
CC         IsoId=P03366-1; Sequence=Displayed;
CC         Note=Produced by -1 ribosomal frameshifting.;
CC       Name=Gag polyprotein;
CC         IsoId=P03347-1; Sequence=External;
CC         Note=Produced by conventional translation.;
CC   -!- DOMAIN: Reverse transcriptase/ribonuclease H: RT is structured in
CC       five subdomains: finger, palm, thumb, connection and RNase H.
CC       Within the palm subdomain, the 'primer grip' region is thought to
CC       be involved in the positioning of the primer terminus for
CC       accommodating the incoming nucleotide. The RNase H domain
CC       stabilizes the association of RT with primer-template.
CC       {ECO:0000250}.
CC   -!- DOMAIN: Reverse transcriptase/ribonuclease H: The tryptophan
CC       repeat motif is involved in RT p66/p51 dimerization (By
CC       similarity). {ECO:0000250}.
CC   -!- DOMAIN: Integrase: The core domain contains the D-x(n)-D-x(35)-E
CC       motif, named for the phylogenetically conserved glutamic acid and
CC       aspartic acid residues and the invariant 35 amino acid spacing
CC       between the second and third acidic residues. Each acidic residue
CC       of the D,D(35)E motif is independently essential for the 3'-
CC       processing and strand transfer activities of purified integrase
CC       protein. {ECO:0000250}.
CC   -!- PTM: Gag-Pol polyprotein: Specific enzymatic cleavages by the
CC       viral protease yield mature proteins. The protease is released by
CC       autocatalytic cleavage. The polyprotein is cleaved during and
CC       after budding, this process is termed maturation. Proteolytic
CC       cleavage of p66 RT removes the RNase H domain to yield the p51 RT
CC       subunit. Nucleocapsid protein p7 might be further cleaved after
CC       virus entry. {ECO:0000250|UniProtKB:P04585, ECO:0000255|PROSITE-
CC       ProRule:PRU00405}.
CC   -!- PTM: Matrix protein p17: Tyrosine phosphorylated presumably in the
CC       virion by a host kinase. Phosphorylation is apparently not a major
CC       regulator of membrane association. {ECO:0000250|UniProtKB:P04585}.
CC   -!- PTM: Capsid protein p24: Phosphorylated possibly by host MAPK1;
CC       this phosphorylation is necessary for Pin1-mediated virion
CC       uncoating. {ECO:0000250|UniProtKB:P12497}.
CC   -!- PTM: Nucleocapsid protein p7: Methylated by host PRMT6, impairing
CC       its function by reducing RNA annealing and the initiation of
CC       reverse transcription. {ECO:0000269|PubMed:17415034}.
CC   -!- MISCELLANEOUS: Reverse transcriptase/ribonuclease H: Error-prone
CC       enzyme that lacks a proof-reading function. High mutations rate is
CC       a direct consequence of this characteristic. RT also displays
CC       frequent template switching leading to high recombination rate.
CC       Recombination mostly occurs between homologous regions of the two
CC       copackaged RNA genomes. If these two RNA molecules derive from
CC       different viral strains, reverse transcription will give rise to
CC       highly recombinated proviral DNAs. {ECO:0000250}.
CC   -!- MISCELLANEOUS: HIV-1 lineages are divided in three main groups, M
CC       (for Major), O (for Outlier), and N (for New, or Non-M, Non-O).
CC       The vast majority of strains found worldwide belong to the group
CC       M. Group O seems to be endemic to and largely confined to Cameroon
CC       and neighboring countries in West Central Africa, where these
CC       viruses represent a small minority of HIV-1 strains. The group N
CC       is represented by a limited number of isolates from Cameroonian
CC       persons. The group M is further subdivided in 9 clades or subtypes
CC       (A to D, F to H, J and K).
CC   -!- MISCELLANEOUS: Resistance to inhibitors associated with mutations
CC       are observed both in viral protease and in reverse transcriptase.
CC       Most of the time, single mutations confer only a modest reduction
CC       in drug susceptibility. Combination of several mutations is
CC       usually required to develop a high-level drug resistance. These
CC       mutations are predominantly found in clade B viruses and not in
CC       other genotypes. They are listed in the clade B representative
CC       isolate HXB2 (AC P04585).
CC   -!- SIMILARITY: Contains 2 CCHC-type zinc fingers.
CC       {ECO:0000255|PROSITE-ProRule:PRU00047}.
CC   -!- SIMILARITY: Contains 1 integrase catalytic domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00457}.
CC   -!- SIMILARITY: Contains 1 integrase-type DNA-binding domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00506}.
CC   -!- SIMILARITY: Contains 1 integrase-type zinc finger.
CC       {ECO:0000255|PROSITE-ProRule:PRU00450}.
CC   -!- SIMILARITY: Contains 1 peptidase A2 domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00275}.
CC   -!- SIMILARITY: Contains 1 reverse transcriptase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00405}.
CC   -!- SIMILARITY: Contains 1 RNase H domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00408}.
CC   -!- WEB RESOURCE: Name=HIV drug resistance mutations;
CC       URL="https://www.iasusa.org/content/hiv-drug-resistance-mutations";
CC   -!- WEB RESOURCE: Name=hivdb; Note=HIV drug resistance database;
CC       URL="http://hivdb.stanford.edu";
CC   -!- WEB RESOURCE: Name=BioAfrica: HIV bioinformatics in Africa;
CC       URL="http://www.bioafrica.net/index.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M15654; AAA44198.1; ALT_SEQ; Genomic_RNA.
DR   EMBL; K02083; AAB59867.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; X01762; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   PIR; A03965; GNVWH3.
DR   PIR; A03967; GNVWVL.
DR   PDB; 1A9M; X-ray; 2.30 A; A/B=501-599.
DR   PDB; 1AJV; X-ray; 2.00 A; A/B=501-599.
DR   PDB; 1AJX; X-ray; 2.00 A; A/B=501-599.
DR   PDB; 1AXA; X-ray; 2.00 A; A/B=501-599.
DR   PDB; 1BQM; X-ray; 3.10 A; A=600-1155, B=600-1029.
DR   PDB; 1BQN; X-ray; 3.30 A; A=600-1440, B=600-1029.
DR   PDB; 1D4H; X-ray; 1.81 A; A/B=501-599.
DR   PDB; 1D4I; X-ray; 1.81 A; A/B=501-599.
DR   PDB; 1D4J; X-ray; 1.81 A; A/B=501-599.
DR   PDB; 1DLO; X-ray; 2.70 A; A=600-1155, B=600-1026.
DR   PDB; 1DW6; X-ray; 1.88 A; C/D=501-599.
DR   PDB; 1EBK; X-ray; 2.06 A; C/D/E/F=501-599.
DR   PDB; 1EBW; X-ray; 1.81 A; A/B=501-599.
DR   PDB; 1EBY; X-ray; 2.29 A; A/B=501-599.
DR   PDB; 1EBZ; X-ray; 2.01 A; A/B=501-599.
DR   PDB; 1EC0; X-ray; 1.79 A; A/B=501-599.
DR   PDB; 1EC1; X-ray; 2.10 A; A/B=501-599.
DR   PDB; 1EC2; X-ray; 2.00 A; A/B=501-599.
DR   PDB; 1EC3; X-ray; 1.80 A; A/B=501-599.
DR   PDB; 1EET; X-ray; 2.73 A; A=600-1156, B=600-1026.
DR   PDB; 1G35; X-ray; 1.80 A; A/B=501-599.
DR   PDB; 1GNM; X-ray; 2.30 A; A/B=501-599.
DR   PDB; 1GNN; X-ray; 2.30 A; A/B=501-599.
DR   PDB; 1GNO; X-ray; 2.30 A; A/B=501-599.
DR   PDB; 1HAR; X-ray; 2.20 A; A=600-815.
DR   PDB; 1HBV; X-ray; 2.30 A; A/B=501-599.
DR   PDB; 1HEF; X-ray; 2.20 A; E=501-599.
DR   PDB; 1HEG; X-ray; 2.20 A; E=501-599.
DR   PDB; 1HIH; X-ray; 2.20 A; A/B=501-599.
DR   PDB; 1HMV; X-ray; 3.20 A; A/C/E/G=600-1159, B/D/F/H=600-1039.
DR   PDB; 1HNI; X-ray; 2.80 A; A=600-1157.
DR   PDB; 1HNV; X-ray; 3.00 A; A=600-1157, B=600-1026.
DR   PDB; 1HOS; X-ray; 2.30 A; A/B=501-599.
DR   PDB; 1HPS; X-ray; 2.30 A; A/B=501-599.
DR   PDB; 1HPZ; X-ray; 3.00 A; A=600-1159, B=600-1029.
DR   PDB; 1HQE; X-ray; 2.70 A; A=600-1159, B=600-1029.
DR   PDB; 1HQU; X-ray; 2.70 A; A=600-1159, B=600-1029.
DR   PDB; 1HRH; X-ray; 2.40 A; A/B=1026-1161.
DR   PDB; 1HTE; X-ray; 2.80 A; A/B=501-599.
DR   PDB; 1HTF; X-ray; 2.20 A; A/B=501-599.
DR   PDB; 1HTG; X-ray; 2.00 A; A/B=501-599.
DR   PDB; 1HVI; X-ray; 1.80 A; A/B=501-599.
DR   PDB; 1HVK; X-ray; 1.80 A; A/B=501-599.
DR   PDB; 1HVP; Model; -; A/B=501-599.
DR   PDB; 1HVU; X-ray; 4.75 A; A/D/G/J=600-1153, B/E/H/K=604-1026.
DR   PDB; 1HYS; X-ray; 3.00 A; A=600-1152, B=600-1024.
DR   PDB; 1IKV; X-ray; 3.00 A; A=600-1159, B=600-1026.
DR   PDB; 1IKW; X-ray; 3.00 A; A=600-1159, B=600-1026.
DR   PDB; 1IKX; X-ray; 2.80 A; A=600-1159, B=600-1026.
DR   PDB; 1IKY; X-ray; 3.00 A; A=600-1159, B=600-1026.
DR   PDB; 1J5O; X-ray; 3.50 A; A=600-1157, B=600-1029.
DR   PDB; 1KJH; X-ray; 2.00 A; P=1155-1164.
DR   PDB; 1MER; X-ray; 1.90 A; A/B=501-599.
DR   PDB; 1MES; X-ray; 1.90 A; A/B=501-599.
DR   PDB; 1MET; X-ray; 1.90 A; A/B=501-599.
DR   PDB; 1MEU; X-ray; 1.90 A; A/B=501-599.
DR   PDB; 1N5Y; X-ray; 3.10 A; A=600-1157, B=600-1029.
DR   PDB; 1N6Q; X-ray; 3.00 A; A=600-1157, B=600-1029.
DR   PDB; 1NPA; X-ray; 2.00 A; A/B=501-599.
DR   PDB; 1NPV; X-ray; 2.00 A; A/B=501-599.
DR   PDB; 1NPW; X-ray; 2.00 A; A/B=501-599.
DR   PDB; 1QE1; X-ray; 2.85 A; A=600-1157, B=600-1026.
DR   PDB; 1QMC; NMR; -; A/B=1379-1429.
DR   PDB; 1R0A; X-ray; 2.80 A; A=600-1157, B=600-1028.
DR   PDB; 1RDH; X-ray; 2.80 A; A/B=1026-1159.
DR   PDB; 1RTD; X-ray; 3.20 A; A/C=600-1153.
DR   PDB; 1RVL; Model; -; A=600-1155, B=600-1027.
DR   PDB; 1RVM; Model; -; A=600-1155, B=600-1027.
DR   PDB; 1RVN; Model; -; A=600-1155, B=600-1027.
DR   PDB; 1RVO; Model; -; A=600-1155, B=600-1027.
DR   PDB; 1RVP; Model; -; A=600-1155, B=600-1027.
DR   PDB; 1RVQ; Model; -; A=600-1155, B=600-1027.
DR   PDB; 1RVR; Model; -; A=600-1155, B=600-1027.
DR   PDB; 1S6P; X-ray; 2.90 A; A=600-1159, B=600-1029.
DR   PDB; 1S6Q; X-ray; 3.00 A; A=600-1159, B=600-1029.
DR   PDB; 1S9E; X-ray; 2.60 A; A=600-1159, B=600-1029.
DR   PDB; 1S9G; X-ray; 2.80 A; A=600-1159, B=600-1029.
DR   PDB; 1SBG; X-ray; 2.30 A; A/B=501-599.
DR   PDB; 1SUQ; X-ray; 3.00 A; A=600-1159, B=600-1029.
DR   PDB; 1SV5; X-ray; 2.90 A; A=600-1159, B=600-1029.
DR   PDB; 1T03; X-ray; 3.10 A; A=600-1157, B=600-1028.
DR   PDB; 1T05; X-ray; 3.00 A; A=600-1157.
DR   PDB; 1T7K; X-ray; 2.10 A; A/B=501-599.
DR   PDB; 1TV6; X-ray; 2.80 A; A=600-1159, B=600-1039.
DR   PDB; 1TVR; X-ray; 3.00 A; A=600-1157, B=600-1026.
DR   PDB; 1UWB; X-ray; 3.20 A; A=600-1157, B=600-1026.
DR   PDB; 1W5V; X-ray; 1.80 A; A/B=490-599.
DR   PDB; 1W5W; X-ray; 1.80 A; A/B=490-599.
DR   PDB; 1W5X; X-ray; 1.90 A; A/B=490-599.
DR   PDB; 1W5Y; X-ray; 1.90 A; A/B=490-599.
DR   PDB; 1YT9; X-ray; 3.00 A; A/B=501-599.
DR   PDB; 1ZP8; X-ray; 2.02 A; A=501-599.
DR   PDB; 1ZPA; X-ray; 2.02 A; A=501-599.
DR   PDB; 1ZSF; X-ray; 1.98 A; A/B=501-599.
DR   PDB; 1ZSR; X-ray; 2.06 A; A/B=501-599.
DR   PDB; 2AQU; X-ray; 2.00 A; A/B=501-599.
DR   PDB; 2B5J; X-ray; 2.90 A; A=600-1159, B=600-1029.
DR   PDB; 2B6A; X-ray; 2.65 A; A=600-1159, B=600-1029.
DR   PDB; 2BAN; X-ray; 2.95 A; A=600-1159, B=600-1029.
DR   PDB; 2BBB; X-ray; 1.70 A; A/B=501-599.
DR   PDB; 2BE2; X-ray; 2.43 A; A=600-1159, B=600-1029.
DR   PDB; 2EXF; NMR; -; A=390-432.
DR   PDB; 2G69; X-ray; 1.35 A; A=501-599.
DR   PDB; 2HB3; X-ray; 1.35 A; A/B=501-598.
DR   PDB; 2HMI; X-ray; 2.80 A; A=600-1157, B=600-1029.
DR   PDB; 2HNZ; X-ray; 3.00 A; B=606-1027.
DR   PDB; 2HS1; X-ray; 0.84 A; A/B=501-599.
DR   PDB; 2HS2; X-ray; 1.22 A; A/B=501-599.
DR   PDB; 2I4D; X-ray; 1.50 A; A/B=501-599.
DR   PDB; 2I4U; X-ray; 1.50 A; A/B=501-599.
DR   PDB; 2I4V; X-ray; 1.50 A; A/B=501-599.
DR   PDB; 2I4W; X-ray; 1.55 A; A/B=501-599.
DR   PDB; 2I4X; X-ray; 1.55 A; A/B=501-599.
DR   PDB; 2I5J; X-ray; 3.15 A; A=600-1150, B=600-1027.
DR   PDB; 2IAJ; X-ray; 2.50 A; A=600-1158, B=600-1045.
DR   PDB; 2IC3; X-ray; 3.00 A; A=600-1158, B=600-1045.
DR   PDB; 2IDW; X-ray; 1.10 A; A/B=501-599.
DR   PDB; 2IEO; X-ray; 1.53 A; A/B=501-599.
DR   PDB; 2JZW; NMR; -; A=390-432.
DR   PDB; 2L45; NMR; -; A=411-429.
DR   PDB; 2L46; NMR; -; A=411-429.
DR   PDB; 2L4L; NMR; -; A=388-432.
DR   PDB; 2UXZ; X-ray; 1.75 A; A/B=501-599.
DR   PDB; 2UY0; X-ray; 1.76 A; A/B=501-599.
DR   PDB; 2VG5; X-ray; 2.80 A; A=600-1156, B=600-1027.
DR   PDB; 2VG6; X-ray; 3.01 A; A=600-1156, B=600-1027.
DR   PDB; 2VG7; X-ray; 2.82 A; A=600-1156, B=600-1027.
DR   PDB; 2X4U; X-ray; 2.10 A; C/F=908-916.
DR   PDB; 2YKM; X-ray; 2.90 A; A=600-1156, B=600-1027.
DR   PDB; 2YKN; X-ray; 2.12 A; A=600-1156, B=600-1027.
DR   PDB; 2ZD1; X-ray; 1.80 A; A=600-1154, B=600-1027.
DR   PDB; 2ZE2; X-ray; 2.90 A; A=600-1154, B=600-1027.
DR   PDB; 3AVI; X-ray; 1.70 A; A/B=1209-1371.
DR   PDB; 3BGR; X-ray; 2.10 A; A=600-1154, B=600-1027.
DR   PDB; 3DLK; X-ray; 1.85 A; A=600-1154, B=605-1027.
DR   PDB; 3GGA; X-ray; 2.50 A; A/B/C/D/G/H=501-599.
DR   PDB; 3GGV; X-ray; 3.09 A; A/B/C/D/E/F/G/H/I=501-599.
DR   PDB; 3GGX; X-ray; 2.70 A; A/B/C/D/E/F/G/H=501-599.
DR   PDB; 3HVT; X-ray; 2.90 A; A=600-1155, B=600-1027.
DR   PDB; 3IG1; X-ray; 2.80 A; A=600-1154, B=600-1027.
DR   PDB; 3IRX; X-ray; 2.80 A; A=600-1154, B=600-1027.
DR   PDB; 3IS9; X-ray; 2.55 A; A=600-1154, B=600-1027.
DR   PDB; 3ISN; X-ray; 2.50 A; C=600-1159, D=600-1026.
DR   PDB; 3ITH; X-ray; 2.80 A; A/C=600-1159, B/D=600-1026.
DR   PDB; 3JSM; X-ray; 3.00 A; A=600-1157, B=600-1028.
DR   PDB; 3JYT; X-ray; 3.30 A; A=600-1157, B=600-1028.
DR   PDB; 3K2P; X-ray; 2.04 A; A/B=1026-1159.
DR   PDB; 3K4V; X-ray; 1.39 A; A/B/C/D=501-599.
DR   PDB; 3KLE; X-ray; 3.20 A; A/E/I/M=600-1157, B/F/J/N=600-1027.
DR   PDB; 3KLF; X-ray; 3.15 A; A/E/I/M=600-1154, B/F/J/N=600-1027.
DR   PDB; 3KLG; X-ray; 3.65 A; A/E=600-1157, B/F=600-1027.
DR   PDB; 3KLH; X-ray; 2.90 A; A=600-1159, B=600-1027.
DR   PDB; 3KLI; X-ray; 2.65 A; A=600-1157, B=600-1027.
DR   PDB; 3NDT; X-ray; 1.72 A; A/B/C/D=501-599.
DR   PDB; 3NU3; X-ray; 1.02 A; A/B=501-599.
DR   PDB; 3NU4; X-ray; 1.20 A; A/B=501-599.
DR   PDB; 3NU5; X-ray; 1.29 A; A/B=501-599.
DR   PDB; 3NU6; X-ray; 1.16 A; A/B=501-599.
DR   PDB; 3NU9; X-ray; 1.85 A; A/B=501-599.
DR   PDB; 3NUJ; X-ray; 1.50 A; A/B=501-599.
DR   PDB; 3NUO; X-ray; 1.35 A; A/B=501-599.
DR   PDB; 3OK9; X-ray; 1.27 A; A/B=501-599.
DR   PDB; 3PSU; X-ray; 2.07 A; A=501-599.
DR   PDB; 3QAA; X-ray; 1.40 A; A/B=501-599.
DR   PDB; 3QLH; X-ray; 2.70 A; A=600-1153, B=605-1027.
DR   PDB; 3QO9; X-ray; 2.60 A; A=600-1154, B=600-1027.
DR   PDB; 3TKG; X-ray; 1.36 A; A/B/C/D=497-599.
DR   PDB; 3TKW; X-ray; 1.55 A; A/B=497-599.
DR   PDB; 3TL9; X-ray; 1.32 A; A/B=497-599.
DR   PDB; 3TLH; X-ray; 2.00 A; A=501-599.
DR   PDB; 3V4I; X-ray; 2.80 A; A/C=600-1153, B/D=600-1027.
DR   PDB; 3V6D; X-ray; 2.70 A; A/C=600-1153, B/D=600-1027.
DR   PDB; 3V81; X-ray; 2.85 A; A/C=600-1153, B/D=600-1027.
DR   PDB; 3ZPS; X-ray; 1.55 A; A/B=501-599.
DR   PDB; 3ZPT; X-ray; 1.54 A; A/B=501-599.
DR   PDB; 3ZPU; X-ray; 1.80 A; A/B=501-599.
DR   PDB; 4COE; X-ray; 2.45 A; A/B=501-599.
DR   PDB; 4CP7; X-ray; 1.80 A; A/B=501-599.
DR   PDB; 4CPQ; X-ray; 2.35 A; A/B=501-599.
DR   PDB; 4CPR; X-ray; 1.80 A; A/B=501-599.
DR   PDB; 4CPS; X-ray; 1.55 A; A/B=501-599.
DR   PDB; 4CPT; X-ray; 1.70 A; A/B=501-599.
DR   PDB; 4CPU; X-ray; 1.82 A; A/B=501-599.
DR   PDB; 4CPW; X-ray; 1.70 A; A/B=501-599.
DR   PDB; 4CPX; X-ray; 1.85 A; A/B=501-599.
DR   PDB; 4DG1; X-ray; 2.15 A; A=600-1148, B=600-1026.
DR   PDB; 4G1Q; X-ray; 1.51 A; A=600-1154, B=600-1027.
DR   PDB; 4G8G; X-ray; 2.40 A; C=263-272.
DR   PDB; 4G8I; X-ray; 1.60 A; C=263-272.
DR   PDB; 4G9D; X-ray; 1.60 A; C=263-272.
DR   PDB; 4G9F; X-ray; 1.90 A; C=263-272.
DR   PDB; 4H4M; X-ray; 2.85 A; A=600-1154, B=600-1027.
DR   PDB; 4H4O; X-ray; 2.90 A; A=600-1154, B=600-1027.
DR   PDB; 4I2P; X-ray; 2.30 A; A=600-1154, B=600-1027.
DR   PDB; 4I2Q; X-ray; 2.70 A; A=600-1154, B=600-1027.
DR   PDB; 4ICL; X-ray; 1.80 A; A=600-1154, B=600-1027.
DR   PDB; 4ID5; X-ray; 1.95 A; A=600-1154, B=600-1027.
DR   PDB; 4IDK; X-ray; 2.10 A; A=600-1154, B=600-1027.
DR   PDB; 4IFV; X-ray; 2.05 A; A=600-1154, B=600-1027.
DR   PDB; 4IFY; X-ray; 2.10 A; A=600-1154, B=600-1027.
DR   PDB; 4IG0; X-ray; 2.50 A; A=600-1154, B=600-1027.
DR   PDB; 4IG3; X-ray; 1.95 A; A=600-1154, B=600-1027.
DR   PDB; 4KFB; X-ray; 1.85 A; A=600-1154, B=604-1027.
DR   PDB; 4KKO; X-ray; 2.89 A; A=600-1154, B=600-1027.
DR   PDB; 4KO0; X-ray; 1.95 A; A=600-1154, B=600-1027.
DR   PDB; 4LSL; X-ray; 2.69 A; A=600-1154, B=600-1027.
DR   PDB; 4LSN; X-ray; 3.10 A; A=600-1154, B=600-1027.
DR   PDB; 4MFB; X-ray; 2.88 A; A=600-1154, B=600-1027.
DR   PDB; 4O44; X-ray; 2.89 A; A=600-1154, B=600-1027.
DR   PDB; 4O4G; X-ray; 2.71 A; A=600-1154, B=600-1027.
DR   PDB; 4OJR; X-ray; 1.82 A; A=1209-1371.
DR   PDB; 4PQU; X-ray; 2.51 A; A/C=600-1153, B/D=600-1027.
DR   PDB; 4PUO; X-ray; 2.90 A; A/C=600-1153, B/D=600-1027.
DR   PDB; 4PWD; X-ray; 3.00 A; A/C=600-1153, B/D=600-1027.
DR   PDB; 4Q0B; X-ray; 3.30 A; A/C=600-1153, B/D=600-1027.
DR   PDB; 4QAG; X-ray; 1.71 A; A/B=1024-1156.
DR   PDB; 4R5P; X-ray; 2.89 A; A/C=600-1153, B/D=600-1027.
DR   PDB; 4RW4; X-ray; 2.67 A; A=600-1154, B=600-1027.
DR   PDB; 4RW6; X-ray; 2.63 A; A=600-1154, B=600-1027.
DR   PDB; 4RW7; X-ray; 3.01 A; A=600-1154, B=600-1027.
DR   PDB; 4RW8; X-ray; 2.88 A; A=600-1154, B=600-1027.
DR   PDB; 4RW9; X-ray; 2.99 A; A=600-1154, B=600-1027.
DR   PDB; 4U8W; X-ray; 1.30 A; A/B=501-599.
DR   PDB; 4WE1; X-ray; 2.49 A; A=600-1154, B=600-1027.
DR   PDB; 5AGZ; X-ray; 1.20 A; A/B=501-599.
DR   PDB; 5AH6; X-ray; 1.50 A; A/B=501-599.
DR   PDB; 5AH7; X-ray; 1.55 A; A/B=501-599.
DR   PDB; 5AH8; X-ray; 1.26 A; A/B=501-599.
DR   PDB; 5AH9; X-ray; 1.44 A; A/B=501-599.
DR   PDB; 5AHA; X-ray; 1.35 A; A/B=501-599.
DR   PDB; 5AHB; X-ray; 1.50 A; A/B=501-599.
DR   PDB; 5AHC; X-ray; 1.50 A; A/B=501-599.
DR   PDBsum; 1A9M; -.
DR   PDBsum; 1AJV; -.
DR   PDBsum; 1AJX; -.
DR   PDBsum; 1AXA; -.
DR   PDBsum; 1BQM; -.
DR   PDBsum; 1BQN; -.
DR   PDBsum; 1D4H; -.
DR   PDBsum; 1D4I; -.
DR   PDBsum; 1D4J; -.
DR   PDBsum; 1DLO; -.
DR   PDBsum; 1DW6; -.
DR   PDBsum; 1EBK; -.
DR   PDBsum; 1EBW; -.
DR   PDBsum; 1EBY; -.
DR   PDBsum; 1EBZ; -.
DR   PDBsum; 1EC0; -.
DR   PDBsum; 1EC1; -.
DR   PDBsum; 1EC2; -.
DR   PDBsum; 1EC3; -.
DR   PDBsum; 1EET; -.
DR   PDBsum; 1G35; -.
DR   PDBsum; 1GNM; -.
DR   PDBsum; 1GNN; -.
DR   PDBsum; 1GNO; -.
DR   PDBsum; 1HAR; -.
DR   PDBsum; 1HBV; -.
DR   PDBsum; 1HEF; -.
DR   PDBsum; 1HEG; -.
DR   PDBsum; 1HIH; -.
DR   PDBsum; 1HMV; -.
DR   PDBsum; 1HNI; -.
DR   PDBsum; 1HNV; -.
DR   PDBsum; 1HOS; -.
DR   PDBsum; 1HPS; -.
DR   PDBsum; 1HPZ; -.
DR   PDBsum; 1HQE; -.
DR   PDBsum; 1HQU; -.
DR   PDBsum; 1HRH; -.
DR   PDBsum; 1HTE; -.
DR   PDBsum; 1HTF; -.
DR   PDBsum; 1HTG; -.
DR   PDBsum; 1HVI; -.
DR   PDBsum; 1HVK; -.
DR   PDBsum; 1HVP; -.
DR   PDBsum; 1HVU; -.
DR   PDBsum; 1HYS; -.
DR   PDBsum; 1IKV; -.
DR   PDBsum; 1IKW; -.
DR   PDBsum; 1IKX; -.
DR   PDBsum; 1IKY; -.
DR   PDBsum; 1J5O; -.
DR   PDBsum; 1KJH; -.
DR   PDBsum; 1MER; -.
DR   PDBsum; 1MES; -.
DR   PDBsum; 1MET; -.
DR   PDBsum; 1MEU; -.
DR   PDBsum; 1N5Y; -.
DR   PDBsum; 1N6Q; -.
DR   PDBsum; 1NPA; -.
DR   PDBsum; 1NPV; -.
DR   PDBsum; 1NPW; -.
DR   PDBsum; 1QE1; -.
DR   PDBsum; 1QMC; -.
DR   PDBsum; 1R0A; -.
DR   PDBsum; 1RDH; -.
DR   PDBsum; 1RTD; -.
DR   PDBsum; 1RVL; -.
DR   PDBsum; 1RVM; -.
DR   PDBsum; 1RVN; -.
DR   PDBsum; 1RVO; -.
DR   PDBsum; 1RVP; -.
DR   PDBsum; 1RVQ; -.
DR   PDBsum; 1RVR; -.
DR   PDBsum; 1S6P; -.
DR   PDBsum; 1S6Q; -.
DR   PDBsum; 1S9E; -.
DR   PDBsum; 1S9G; -.
DR   PDBsum; 1SBG; -.
DR   PDBsum; 1SUQ; -.
DR   PDBsum; 1SV5; -.
DR   PDBsum; 1T03; -.
DR   PDBsum; 1T05; -.
DR   PDBsum; 1T7K; -.
DR   PDBsum; 1TV6; -.
DR   PDBsum; 1TVR; -.
DR   PDBsum; 1UWB; -.
DR   PDBsum; 1W5V; -.
DR   PDBsum; 1W5W; -.
DR   PDBsum; 1W5X; -.
DR   PDBsum; 1W5Y; -.
DR   PDBsum; 1YT9; -.
DR   PDBsum; 1ZP8; -.
DR   PDBsum; 1ZPA; -.
DR   PDBsum; 1ZSF; -.
DR   PDBsum; 1ZSR; -.
DR   PDBsum; 2AQU; -.
DR   PDBsum; 2B5J; -.
DR   PDBsum; 2B6A; -.
DR   PDBsum; 2BAN; -.
DR   PDBsum; 2BBB; -.
DR   PDBsum; 2BE2; -.
DR   PDBsum; 2EXF; -.
DR   PDBsum; 2G69; -.
DR   PDBsum; 2HB3; -.
DR   PDBsum; 2HMI; -.
DR   PDBsum; 2HNZ; -.
DR   PDBsum; 2HS1; -.
DR   PDBsum; 2HS2; -.
DR   PDBsum; 2I4D; -.
DR   PDBsum; 2I4U; -.
DR   PDBsum; 2I4V; -.
DR   PDBsum; 2I4W; -.
DR   PDBsum; 2I4X; -.
DR   PDBsum; 2I5J; -.
DR   PDBsum; 2IAJ; -.
DR   PDBsum; 2IC3; -.
DR   PDBsum; 2IDW; -.
DR   PDBsum; 2IEO; -.
DR   PDBsum; 2JZW; -.
DR   PDBsum; 2L45; -.
DR   PDBsum; 2L46; -.
DR   PDBsum; 2L4L; -.
DR   PDBsum; 2UXZ; -.
DR   PDBsum; 2UY0; -.
DR   PDBsum; 2VG5; -.
DR   PDBsum; 2VG6; -.
DR   PDBsum; 2VG7; -.
DR   PDBsum; 2X4U; -.
DR   PDBsum; 2YKM; -.
DR   PDBsum; 2YKN; -.
DR   PDBsum; 2ZD1; -.
DR   PDBsum; 2ZE2; -.
DR   PDBsum; 3AVI; -.
DR   PDBsum; 3BGR; -.
DR   PDBsum; 3DLK; -.
DR   PDBsum; 3GGA; -.
DR   PDBsum; 3GGV; -.
DR   PDBsum; 3GGX; -.
DR   PDBsum; 3HVT; -.
DR   PDBsum; 3IG1; -.
DR   PDBsum; 3IRX; -.
DR   PDBsum; 3IS9; -.
DR   PDBsum; 3ISN; -.
DR   PDBsum; 3ITH; -.
DR   PDBsum; 3JSM; -.
DR   PDBsum; 3JYT; -.
DR   PDBsum; 3K2P; -.
DR   PDBsum; 3K4V; -.
DR   PDBsum; 3KLE; -.
DR   PDBsum; 3KLF; -.
DR   PDBsum; 3KLG; -.
DR   PDBsum; 3KLH; -.
DR   PDBsum; 3KLI; -.
DR   PDBsum; 3NDT; -.
DR   PDBsum; 3NU3; -.
DR   PDBsum; 3NU4; -.
DR   PDBsum; 3NU5; -.
DR   PDBsum; 3NU6; -.
DR   PDBsum; 3NU9; -.
DR   PDBsum; 3NUJ; -.
DR   PDBsum; 3NUO; -.
DR   PDBsum; 3OK9; -.
DR   PDBsum; 3PSU; -.
DR   PDBsum; 3QAA; -.
DR   PDBsum; 3QLH; -.
DR   PDBsum; 3QO9; -.
DR   PDBsum; 3TKG; -.
DR   PDBsum; 3TKW; -.
DR   PDBsum; 3TL9; -.
DR   PDBsum; 3TLH; -.
DR   PDBsum; 3V4I; -.
DR   PDBsum; 3V6D; -.
DR   PDBsum; 3V81; -.
DR   PDBsum; 3ZPS; -.
DR   PDBsum; 3ZPT; -.
DR   PDBsum; 3ZPU; -.
DR   PDBsum; 4COE; -.
DR   PDBsum; 4CP7; -.
DR   PDBsum; 4CPQ; -.
DR   PDBsum; 4CPR; -.
DR   PDBsum; 4CPS; -.
DR   PDBsum; 4CPT; -.
DR   PDBsum; 4CPU; -.
DR   PDBsum; 4CPW; -.
DR   PDBsum; 4CPX; -.
DR   PDBsum; 4DG1; -.
DR   PDBsum; 4G1Q; -.
DR   PDBsum; 4G8G; -.
DR   PDBsum; 4G8I; -.
DR   PDBsum; 4G9D; -.
DR   PDBsum; 4G9F; -.
DR   PDBsum; 4H4M; -.
DR   PDBsum; 4H4O; -.
DR   PDBsum; 4I2P; -.
DR   PDBsum; 4I2Q; -.
DR   PDBsum; 4ICL; -.
DR   PDBsum; 4ID5; -.
DR   PDBsum; 4IDK; -.
DR   PDBsum; 4IFV; -.
DR   PDBsum; 4IFY; -.
DR   PDBsum; 4IG0; -.
DR   PDBsum; 4IG3; -.
DR   PDBsum; 4KFB; -.
DR   PDBsum; 4KKO; -.
DR   PDBsum; 4KO0; -.
DR   PDBsum; 4LSL; -.
DR   PDBsum; 4LSN; -.
DR   PDBsum; 4MFB; -.
DR   PDBsum; 4O44; -.
DR   PDBsum; 4O4G; -.
DR   PDBsum; 4OJR; -.
DR   PDBsum; 4PQU; -.
DR   PDBsum; 4PUO; -.
DR   PDBsum; 4PWD; -.
DR   PDBsum; 4Q0B; -.
DR   PDBsum; 4QAG; -.
DR   PDBsum; 4R5P; -.
DR   PDBsum; 4RW4; -.
DR   PDBsum; 4RW6; -.
DR   PDBsum; 4RW7; -.
DR   PDBsum; 4RW8; -.
DR   PDBsum; 4RW9; -.
DR   PDBsum; 4U8W; -.
DR   PDBsum; 4WE1; -.
DR   PDBsum; 5AGZ; -.
DR   PDBsum; 5AH6; -.
DR   PDBsum; 5AH7; -.
DR   PDBsum; 5AH8; -.
DR   PDBsum; 5AH9; -.
DR   PDBsum; 5AHA; -.
DR   PDBsum; 5AHB; -.
DR   PDBsum; 5AHC; -.
DR   ProteinModelPortal; P03366; -.
DR   SMR; P03366; 1-432, 501-1155, 1160-1429.
DR   IntAct; P03366; 38.
DR   MINT; MINT-111903; -.
DR   ChEMBL; CHEMBL5823; -.
DR   BRENDA; 2.7.7.49; 2676.
DR   BRENDA; 3.1.13.2; 2676.
DR   SABIO-RK; P03366; -.
DR   EvolutionaryTrace; P03366; -.
DR   Proteomes; UP000007690; Genome.
DR   GO; GO:0042025; C:host cell nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0072494; C:host multivesicular body; IEA:UniProtKB-SubCell.
DR   GO; GO:0019013; C:viral nucleocapsid; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0004190; F:aspartic-type endopeptidase activity; IEA:UniProtKB-KW.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003887; F:DNA-directed DNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004533; F:exoribonuclease H activity; IEA:UniProtKB-EC.
DR   GO; GO:0008289; F:lipid binding; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003964; F:RNA-directed DNA polymerase activity; IDA:CACAO.
DR   GO; GO:0004523; F:RNA-DNA hybrid ribonuclease activity; IEA:InterPro.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0015074; P:DNA integration; IEA:UniProtKB-KW.
DR   GO; GO:0006310; P:DNA recombination; IEA:UniProtKB-KW.
DR   GO; GO:0075713; P:establishment of integrated proviral latency; IEA:UniProtKB-KW.
DR   GO; GO:0039651; P:induction by virus of host cysteine-type endopeptidase activity involved in apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0039657; P:suppression by virus of host gene expression; IEA:UniProtKB-KW.
DR   GO; GO:0046718; P:viral entry into host cell; IEA:UniProtKB-KW.
DR   GO; GO:0075732; P:viral penetration into host nucleus; IEA:UniProtKB-KW.
DR   GO; GO:0019076; P:viral release from host cell; IEA:UniProtKB-KW.
DR   Gene3D; 1.10.10.200; -; 1.
DR   Gene3D; 1.10.1200.30; -; 1.
DR   Gene3D; 1.10.150.90; -; 1.
DR   Gene3D; 1.10.375.10; -; 1.
DR   Gene3D; 2.30.30.10; -; 1.
DR   Gene3D; 2.40.70.10; -; 1.
DR   Gene3D; 3.30.420.10; -; 2.
DR   Gene3D; 4.10.60.10; -; 1.
DR   InterPro; IPR001969; Aspartic_peptidase_AS.
DR   InterPro; IPR000721; Gag_p24.
DR   InterPro; IPR001037; Integrase_C_retrovir.
DR   InterPro; IPR001584; Integrase_cat-core.
DR   InterPro; IPR017856; Integrase_Zn-bd_dom-like_N.
DR   InterPro; IPR003308; Integrase_Zn-bd_dom_N.
DR   InterPro; IPR000071; Lentvrl_matrix_N.
DR   InterPro; IPR012344; Matrix_HIV/RSV.
DR   InterPro; IPR018061; Pept_A2A_retrovirus_sg.
DR   InterPro; IPR001995; Peptidase_A2_cat.
DR   InterPro; IPR021109; Peptidase_aspartic_dom.
DR   InterPro; IPR008916; Retrov_capsid_C.
DR   InterPro; IPR008919; Retrov_capsid_N.
DR   InterPro; IPR010999; Retrovr_matrix.
DR   InterPro; IPR012337; RNaseH-like_dom.
DR   InterPro; IPR002156; RNaseH_domain.
DR   InterPro; IPR000477; RT_dom.
DR   InterPro; IPR010659; RVT_connect.
DR   InterPro; IPR010661; RVT_thumb.
DR   InterPro; IPR001878; Znf_CCHC.
DR   Pfam; PF00540; Gag_p17; 1.
DR   Pfam; PF00607; Gag_p24; 1.
DR   Pfam; PF00552; IN_DBD_C; 1.
DR   Pfam; PF02022; Integrase_Zn; 1.
DR   Pfam; PF00075; RNase_H; 1.
DR   Pfam; PF00665; rve; 1.
DR   Pfam; PF00077; RVP; 1.
DR   Pfam; PF00078; RVT_1; 1.
DR   Pfam; PF06815; RVT_connect; 1.
DR   Pfam; PF06817; RVT_thumb; 1.
DR   Pfam; PF00098; zf-CCHC; 2.
DR   PRINTS; PR00234; HIV1MATRIX.
DR   SMART; SM00343; ZnF_C2HC; 2.
DR   SUPFAM; SSF46919; SSF46919; 1.
DR   SUPFAM; SSF47353; SSF47353; 1.
DR   SUPFAM; SSF47836; SSF47836; 1.
DR   SUPFAM; SSF47943; SSF47943; 1.
DR   SUPFAM; SSF50122; SSF50122; 1.
DR   SUPFAM; SSF50630; SSF50630; 1.
DR   SUPFAM; SSF53098; SSF53098; 2.
DR   SUPFAM; SSF57756; SSF57756; 1.
DR   PROSITE; PS50175; ASP_PROT_RETROV; 1.
DR   PROSITE; PS00141; ASP_PROTEASE; 1.
DR   PROSITE; PS50994; INTEGRASE; 1.
DR   PROSITE; PS51027; INTEGRASE_DBD; 1.
DR   PROSITE; PS50879; RNASE_H; 1.
DR   PROSITE; PS50878; RT_POL; 1.
DR   PROSITE; PS50158; ZF_CCHC; 2.
DR   PROSITE; PS50876; ZF_INTEGRASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activation of host caspases by virus; AIDS;
KW   Aspartyl protease; Capsid protein; Complete proteome; DNA integration;
KW   DNA recombination; DNA-binding; DNA-directed DNA polymerase;
KW   Endonuclease; Eukaryotic host gene expression shutoff by virus;
KW   Eukaryotic host translation shutoff by virus; Host cell membrane;
KW   Host cytoplasm; Host endosome; Host gene expression shutoff by virus;
KW   Host membrane; Host nucleus; Host-virus interaction; Hydrolase;
KW   Lipid-binding; Lipoprotein; Magnesium; Membrane; Metal-binding;
KW   Methylation; Modulation of host cell apoptosis by virus;
KW   Multifunctional enzyme; Myristate; Nuclease; Nucleotidyltransferase;
KW   Phosphoprotein; Protease; Repeat; Ribosomal frameshifting;
KW   RNA-binding; RNA-directed DNA polymerase; Transferase;
KW   Viral genome integration; Viral nucleoprotein;
KW   Viral penetration into host nucleus; Virion; Virion maturation;
KW   Virus entry into host cell; Virus exit from host cell; Zinc;
KW   Zinc-finger.
FT   INIT_MET      1      1       Removed; by host. {ECO:0000250}.
FT   CHAIN         2   1447       Gag-Pol polyprotein.
FT                                /FTId=PRO_0000261261.
FT   CHAIN         2    132       Matrix protein p17. {ECO:0000250}.
FT                                /FTId=PRO_0000042285.
FT   CHAIN       133    363       Capsid protein p24. {ECO:0000250}.
FT                                /FTId=PRO_0000042286.
FT   PEPTIDE     364    377       Spacer peptide 1. {ECO:0000250}.
FT                                /FTId=PRO_0000042287.
FT   CHAIN       378    432       Nucleocapsid protein p7. {ECO:0000250}.
FT                                /FTId=PRO_0000042288.
FT   PEPTIDE     433    440       Transframe peptide. {ECO:0000255}.
FT                                /FTId=PRO_0000246710.
FT   CHAIN       441    500       p6-pol. {ECO:0000255}.
FT                                /FTId=PRO_0000042289.
FT   CHAIN       501    599       Protease. {ECO:0000250}.
FT                                /FTId=PRO_0000038647.
FT   CHAIN       600   1159       Reverse transcriptase/ribonuclease H.
FT                                {ECO:0000250}.
FT                                /FTId=PRO_0000042290.
FT   CHAIN       600   1039       p51 RT. {ECO:0000250}.
FT                                /FTId=PRO_0000042291.
FT   CHAIN      1040   1159       p15.
FT                                /FTId=PRO_0000042292.
FT   CHAIN      1160   1447       Integrase. {ECO:0000250}.
FT                                /FTId=PRO_0000042293.
FT   DOMAIN      520    589       Peptidase A2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00275}.
FT   DOMAIN      643    833       Reverse transcriptase.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00405}.
FT   DOMAIN     1033   1156       RNase H. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00408}.
FT   DOMAIN     1213   1363       Integrase catalytic.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00457}.
FT   ZN_FING     390    407       CCHC-type 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00047}.
FT   ZN_FING     411    428       CCHC-type 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00047}.
FT   ZN_FING    1162   1203       Integrase-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00450}.
FT   DNA_BIND   1382   1429       Integrase-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00506}.
FT   REGION        7     31       Interaction with Gp41.
FT                                {ECO:0000250|UniProtKB:P12497}.
FT   REGION        8     43       Interaction with host CALM1.
FT                                {ECO:0000250|UniProtKB:P04585}.
FT   REGION       12     19       Interaction with host AP3D1.
FT                                {ECO:0000250|UniProtKB:P12497}.
FT   REGION       14     33       Interaction with membrane
FT                                phosphatidylinositol 4,5-bisphosphate and
FT                                RNA. {ECO:0000250|UniProtKB:P12497}.
FT   REGION       73     77       Interaction with membrane
FT                                phosphatidylinositol 4,5-bisphosphate.
FT                                {ECO:0000250|UniProtKB:P12497}.
FT   REGION      189    227       Interaction with human PPIA/CYPA and
FT                                NUP153. {ECO:0000250|UniProtKB:P12497}.
FT   REGION      277    363       Dimerization/Multimerization of capsid
FT                                protein p24.
FT                                {ECO:0000250|UniProtKB:P04585}.
FT   REGION      501    505       Dimerization of protease.
FT                                {ECO:0000250|UniProtKB:P04585}.
FT   REGION      549    555       Dimerization of protease.
FT                                {ECO:0000250|UniProtKB:P04585}.
FT   REGION      588    600       Dimerization of protease.
FT                                {ECO:0000250|UniProtKB:P04585}.
FT   REGION      826    834       RT 'primer grip'.
FT   MOTIF        16     22       Nuclear export signal. {ECO:0000250}.
FT   MOTIF        26     32       Nuclear localization signal.
FT                                {ECO:0000250}.
FT   MOTIF       997   1013       Tryptophan repeat motif.
FT   ACT_SITE    525    525       For protease activity; shared with
FT                                dimeric partner. {ECO:0000255|PROSITE-
FT                                ProRule:PRU10094,
FT                                ECO:0000269|PubMed:12924029}.
FT   METAL       709    709       Magnesium; catalytic; for reverse
FT                                transcriptase activity.
FT   METAL       784    784       Magnesium; catalytic; for reverse
FT                                transcriptase activity.
FT   METAL       785    785       Magnesium; catalytic; for reverse
FT                                transcriptase activity.
FT   METAL      1042   1042       Magnesium; catalytic; for RNase H
FT                                activity. {ECO:0000305}.
FT   METAL      1077   1077       Magnesium; catalytic; for RNase H
FT                                activity. {ECO:0000305}.
FT   METAL      1097   1097       Magnesium; catalytic; for RNase H
FT                                activity. {ECO:0000305}.
FT   METAL      1148   1148       Magnesium; catalytic; for RNase H
FT                                activity. {ECO:0000305}.
FT   METAL      1223   1223       Magnesium; catalytic; for integrase
FT                                activity. {ECO:0000250}.
FT   METAL      1275   1275       Magnesium; catalytic; for integrase
FT                                activity. {ECO:0000250}.
FT   METAL      1311   1311       Magnesium; catalytic; for integrase
FT                                activity. {ECO:0000250|UniProtKB:P04585}.
FT   SITE        132    133       Cleavage; by viral protease.
FT                                {ECO:0000250}.
FT   SITE        221    222       Cis/trans isomerization of proline
FT                                peptide bond; by human PPIA/CYPA.
FT                                {ECO:0000250}.
FT   SITE        363    364       Cleavage; by viral protease.
FT                                {ECO:0000250}.
FT   SITE        377    378       Cleavage; by viral protease.
FT                                {ECO:0000250}.
FT   SITE        432    433       Cleavage; by viral protease.
FT                                {ECO:0000255}.
FT   SITE        440    441       Cleavage; by viral protease.
FT   SITE        500    501       Cleavage; by viral protease.
FT   SITE        599    600       Cleavage; by viral protease.
FT                                {ECO:0000250}.
FT   SITE       1000   1000       Essential for RT p66/p51
FT                                heterodimerization.
FT   SITE       1013   1013       Essential for RT p66/p51
FT                                heterodimerization.
FT   SITE       1039   1040       Cleavage; by viral protease; partial.
FT   SITE       1159   1160       Cleavage; by viral protease.
FT                                {ECO:0000250}.
FT   MOD_RES     132    132       Phosphotyrosine; by host. {ECO:0000250}.
FT   MOD_RES     387    387       Asymmetric dimethylarginine; in
FT                                Nucleocapsid protein p7; by host PRMT6.
FT                                {ECO:0000269|PubMed:17415034}.
FT   MOD_RES     409    409       Asymmetric dimethylarginine; in
FT                                Nucleocapsid protein p7; by host PRMT6.
FT                                {ECO:0000269|PubMed:17415034}.
FT   LIPID         2      2       N-myristoyl glycine; by host.
FT                                {ECO:0000250}.
FT   VARIANT     297    297       V -> L (in strain: Isolate PV22).
FT   VARIANT     434    434       L -> F.
FT   VARIANT     771    771       K -> R (in strain: Isolate PV22).
FT   VARIANT    1050   1050       K -> R (in strain: Isolate PV22).
FT   VARIANT    1057   1057       V -> L (in strain: Isolate PV22).
FT   VARIANT    1111   1111       K -> Q (in strain: Isolate PV22).
FT   VARIANT    1128   1128       E -> Q (in strain: Isolate PV22).
FT   MUTAGEN     440    440       F->I: Complete loss of cleavage between
FT                                NC and TF. {ECO:0000269|PubMed:11172099}.
FT   MUTAGEN     500    500       F->I: Complete loss of cleavage between
FT                                TF and p15.
FT                                {ECO:0000269|PubMed:11172099}.
FT   MUTAGEN     651    651       P->G: 74% loss of polymerase activity.
FT                                86% loss of RNase H activity.
FT                                {ECO:0000269|PubMed:9533880}.
FT   MUTAGEN     654    654       P->G: 64% loss of polymerase activity.
FT                                57% loss of RNase H activity.
FT                                {ECO:0000269|PubMed:9533880}.
FT   MUTAGEN     664    664       K->A: Strong decrease in RT binding
FT                                affinity for all dNTP substrates and in
FT                                catalytic efficiency. 100-fold decreased
FT                                sensitivity to ddNTP inhibitors.
FT                                {ECO:0000269|PubMed:10794716}.
FT   MUTAGEN     664    664       K->E: Strong decrease in RT binding
FT                                affinity for all dNTP substrates and in
FT                                catalytic efficiency. 100-fold decreased
FT                                sensitivity to ddNTP inhibitors.
FT                                {ECO:0000269|PubMed:10794716}.
FT   MUTAGEN     664    664       K->Q: Strong decrease in RT binding
FT                                affinity for all dNTP substrates and in
FT                                catalytic efficiency. 100-fold decreased
FT                                sensitivity to ddNTP inhibitors.
FT                                {ECO:0000269|PubMed:10794716}.
FT   MUTAGEN     664    664       K->R: 10-fold decreased sensitivity to
FT                                ddATP and ddCTP inhibitors.
FT                                {ECO:0000269|PubMed:10794716}.
FT   MUTAGEN     673    673       L->V: No loss of polymerase activity. No
FT                                loss of RNase H activity.
FT                                {ECO:0000269|PubMed:9533880}.
FT   MUTAGEN     709    709       D->A: 5- to 12-fold decrease in affinity
FT                                for dTTP substrates. Strongly decreased
FT                                RNA-directed and DNA-directed DNA
FT                                polymerase activities. No effect on RNase
FT                                H activity. Loss of pyrophosphorolysis
FT                                (reverse of the polymerase reaction).
FT                                {ECO:0000269|PubMed:8794733}.
FT   MUTAGEN     709    709       D->S: 5- to 12-fold decrease in affinity
FT                                for dTTP substrates. Strongly decreased
FT                                RNA-directed DNA polymerase activity.
FT                                Slightly decreased DNA-directed DNA
FT                                polymerase activity. No effect on RNase H
FT                                activity. Loss of pyrophosphorolysis
FT                                (reverse of the polymerase reaction).
FT                                {ECO:0000269|PubMed:8794733}.
FT   MUTAGEN     752    752       W->A: 73% loss of DNA-directed DNA
FT                                polymerase activity. 70% loss of RNA-
FT                                directed DNA polymerase activity.
FT                                {ECO:0000269|PubMed:12501197}.
FT   MUTAGEN     752    752       W->F: 10% loss of DNA-directed DNA
FT                                polymerase activity. 22% loss of RNA-
FT                                directed DNA polymerase activity.
FT                                {ECO:0000269|PubMed:12501197}.
FT   MUTAGEN     752    752       W->Y: 58% loss of DNA-directed DNA
FT                                polymerase activity. 42% loss of RNA-
FT                                directed DNA polymerase activity.
FT                                {ECO:0000269|PubMed:12501197}.
FT   MUTAGEN     755    755       S->A: 74% loss of polymerase activity.
FT                                56% loss of RNase H activity.
FT                                {ECO:0000269|PubMed:9533880}.
FT   MUTAGEN     755    755       S->G: Complete loss of polymerase
FT                                activity. No loss of RNase H activity.
FT                                {ECO:0000269|PubMed:9533880}.
FT   MUTAGEN     755    755       S->T: Complete loss of polymerase
FT                                activity. No loss of RNase H activity.
FT                                {ECO:0000269|PubMed:9533880}.
FT   MUTAGEN     756    756       P->G: 34% loss of polymerase activity. No
FT                                loss of RNase H activity.
FT                                {ECO:0000269|PubMed:9533880}.
FT   MUTAGEN     766    766       I->A: 71% loss of DNA-directed DNA
FT                                polymerase activity. 61% loss of RNA-
FT                                directed DNA polymerase activity.
FT                                {ECO:0000269|PubMed:12501197}.
FT   MUTAGEN     766    766       I->D: 16% loss of DNA-directed DNA
FT                                polymerase activity. 24% loss of RNA-
FT                                directed DNA polymerase activity.
FT                                {ECO:0000269|PubMed:12501197}.
FT   MUTAGEN     766    766       I->L: 80% loss of DNA-directed DNA
FT                                polymerase activity. 23% loss of RNA-
FT                                directed DNA polymerase activity.
FT                                {ECO:0000269|PubMed:12501197}.
FT   MUTAGEN     766    766       I->T: 34% increase of DNA-directed DNA
FT                                polymerase activity. 18% increase of RNA-
FT                                directed DNA polymerase activity.
FT                                {ECO:0000269|PubMed:12501197}.
FT   MUTAGEN     766    766       I->V: 70% loss of DNA-directed DNA
FT                                polymerase activity. 64% loss of RNA-
FT                                directed DNA polymerase activity.
FT                                {ECO:0000269|PubMed:12501197}.
FT   MUTAGEN     782    782       Y->A: Almost complete loss of polymerase
FT                                activity. {ECO:0000269|PubMed:9657675}.
FT   MUTAGEN     782    782       Y->F: 70% loss of polymerase activity. No
FT                                loss of polymerase activity; when
FT                                associated with V-783.
FT                                {ECO:0000269|PubMed:9657675}.
FT   MUTAGEN     783    783       M->I: 54% loss of polymerase activity
FT                                according to PubMed:9533880; increases
FT                                polymerase activity according to
FT                                PubMed:9657675. No loss of RNase H
FT                                activity. {ECO:0000269|PubMed:9533880,
FT                                ECO:0000269|PubMed:9657675}.
FT   MUTAGEN     783    783       M->L: 90% loss of polymerase activity. No
FT                                loss of RNase H activity.
FT                                {ECO:0000269|PubMed:9533880,
FT                                ECO:0000269|PubMed:9657675}.
FT   MUTAGEN     783    783       M->V: 58% loss of polymerase activity. No
FT                                loss of RNase H activity.
FT                                {ECO:0000269|PubMed:9533880,
FT                                ECO:0000269|PubMed:9657675}.
FT   MUTAGEN     784    784       D->A: Strongly decreased RNA-directed and
FT                                DNA-directed DNA polymerase activities.
FT                                No effect on RNase H activity.
FT                                {ECO:0000269|PubMed:8794733,
FT                                ECO:0000269|PubMed:9657675}.
FT   MUTAGEN     784    784       D->E: Strongly decreased RNA-directed and
FT                                DNA-directed DNA polymerase activities.
FT                                No effect on RNase H activity.
FT                                {ECO:0000269|PubMed:8794733,
FT                                ECO:0000269|PubMed:9657675}.
FT   MUTAGEN     784    784       D->N: Strongly decreased RNA-directed and
FT                                DNA-directed DNA polymerase activities.
FT                                No effect on RNase H activity.
FT                                {ECO:0000269|PubMed:8794733,
FT                                ECO:0000269|PubMed:9657675}.
FT   MUTAGEN     785    785       D->A: Strongly decreased RNA-directed and
FT                                DNA-directed DNA polymerase activities.
FT                                Loss of pyrophosphorolysis (reverse of
FT                                the polymerase reaction). No effect on
FT                                RNase H activity.
FT                                {ECO:0000269|PubMed:8794733,
FT                                ECO:0000269|PubMed:9657675}.
FT   MUTAGEN     785    785       D->E: Drastically reduced incorporation
FT                                of phosphorothioate nucleotide. Loss of
FT                                pyrophosphorolysis (reverse of the
FT                                polymerase reaction). No effect on RNase
FT                                H activity. {ECO:0000269|PubMed:8794733,
FT                                ECO:0000269|PubMed:9657675}.
FT   MUTAGEN     785    785       D->N: Loss of pyrophosphorolysis (reverse
FT                                of the polymerase reaction). No effect on
FT                                RNase H activity.
FT                                {ECO:0000269|PubMed:8794733,
FT                                ECO:0000269|PubMed:9657675}.
FT   MUTAGEN     786    786       L->A: 76% loss of DNA-directed DNA
FT                                polymerase activity. 60% loss of RNA-
FT                                directed DNA polymerase activity.
FT                                {ECO:0000269|PubMed:12501197}.
FT   MUTAGEN     786    786       L->I: 29% loss of DNA-directed DNA
FT                                polymerase activity. 46% loss of RNA-
FT                                directed DNA polymerase activity.
FT                                {ECO:0000269|PubMed:12501197}.
FT   MUTAGEN     786    786       L->R: 20% loss of DNA-directed DNA
FT                                polymerase activity. 21% loss of RNA-
FT                                directed DNA polymerase activity.
FT                                {ECO:0000269|PubMed:12501197}.
FT   MUTAGEN     786    786       L->V: 22% loss of DNA-directed DNA
FT                                polymerase activity. No loss of RNA-
FT                                directed DNA polymerase activity.
FT                                {ECO:0000269|PubMed:12501197}.
FT   MUTAGEN     788    788       V->A: 37% increase of DNA-directed DNA
FT                                polymerase activity. No loss of RNA-
FT                                directed DNA polymerase activity.
FT                                {ECO:0000269|PubMed:12501197}.
FT   MUTAGEN     788    788       V->I: 25% increase of DNA-directed DNA
FT                                polymerase activity. No loss of RNA-
FT                                directed DNA polymerase activity.
FT                                {ECO:0000269|PubMed:12501197}.
FT   MUTAGEN     788    788       V->M: 27% increase of DNA-directed DNA
FT                                polymerase activity. 10% loss of RNA-
FT                                directed DNA polymerase activity.
FT                                {ECO:0000269|PubMed:12501197}.
FT   MUTAGEN     823    823       E->A: No effect on RNA-dependent DNA
FT                                polymerase activity. No effect on RNA 5'-
FT                                end and 3'-end cleavages.
FT                                {ECO:0000269|PubMed:9111014}.
FT   MUTAGEN     824    824       P->A: No effect on RNA-dependent DNA
FT                                polymerase activity. No effect on RNA 5'-
FT                                end and 3'-end cleavages.
FT                                {ECO:0000269|PubMed:9111014}.
FT   MUTAGEN     825    825       P->A: No effect on RNA-dependent DNA
FT                                polymerase activity. Complete loss of RNA
FT                                5'-end cleavage. No effect on RNA 3'-end
FT                                cleavage. {ECO:0000269|PubMed:9111014}.
FT   MUTAGEN     826    826       F->A: No effect on RNA-dependent DNA
FT                                polymerase activity. Complete loss of RNA
FT                                5'-end cleavage. No effect on RNA 3'-end
FT                                cleavage. {ECO:0000269|PubMed:9111014}.
FT   MUTAGEN     827    827       L->A: No effect on RNA-dependent DNA
FT                                polymerase activity. No effect on RNA 5'-
FT                                end and 3'-end cleavages.
FT                                {ECO:0000269|PubMed:9111014}.
FT   MUTAGEN     828    828       W->A: Complete loss of RNA-dependent DNA
FT                                polymerase activity. No effect on RNA 5'-
FT                                end and 3'-end cleavages.
FT                                {ECO:0000269|PubMed:9111014}.
FT   MUTAGEN     829    829       M->A: No effect on RNA-dependent DNA
FT                                polymerase activity. No effect on RNA 5'-
FT                                end and 3'-end cleavages.
FT                                {ECO:0000269|PubMed:9111014}.
FT   MUTAGEN     830    830       G->A: Complete loss of RNA-dependent DNA
FT                                polymerase activity. Complete loss of RNA
FT                                5'-end and 3'-end cleavages.
FT                                {ECO:0000269|PubMed:9111014}.
FT   MUTAGEN     831    831       Y->A: Complete loss of RNA-dependent DNA
FT                                polymerase activity. Complete loss of RNA
FT                                5'-end and 3'-end cleavages.
FT                                {ECO:0000269|PubMed:9111014}.
FT   MUTAGEN     832    832       E->A: Complete loss of RNA-dependent DNA
FT                                polymerase activity. Complete loss of RNA
FT                                5'-end and 3'-end cleavages.
FT                                {ECO:0000269|PubMed:9111014}.
FT   MUTAGEN     834    834       H->A: Complete loss of RNA-dependent DNA
FT                                polymerase activity. Complete loss of RNA
FT                                5'-end and 3'-end cleavages.
FT                                {ECO:0000269|PubMed:9111014}.
FT   MUTAGEN     856    856       I->T: 96% loss of polymerase activity.
FT                                45% loss of RNase H activity.
FT                                {ECO:0000269|PubMed:9533880}.
FT   MUTAGEN     861    861       G->A: Complete loss of polymerase
FT                                activity. 25% loss of RNase H activity.
FT                                {ECO:0000269|PubMed:9533880}.
FT   MUTAGEN     863    863       L->S: 17% loss of polymerase activity.
FT                                30% loss of RNase H activity.
FT                                {ECO:0000269|PubMed:9533880}.
FT   MUTAGEN     865    865       W->T: Complete loss of polymerase
FT                                activity. 87% loss of RNase H activity.
FT                                {ECO:0000269|PubMed:9533880}.
FT   MUTAGEN     878    878       L->S: 21% loss of polymerase activity.
FT                                16% loss of RNase H activity.
FT                                {ECO:0000269|PubMed:9533880}.
FT   MUTAGEN     898    898       A->L: 68% loss of polymerase activity.
FT                                10% loss of RNase H activity.
FT                                {ECO:0000269|PubMed:9533880}.
FT   MUTAGEN     902    902       L->S: 59% loss of polymerase activity. 8%
FT                                loss of RNase H activity.
FT                                {ECO:0000269|PubMed:9533880}.
FT   MUTAGEN     909    909       L->S: 31% loss of polymerase activity. No
FT                                loss of RNase H activity.
FT                                {ECO:0000269|PubMed:9533880}.
FT   MUTAGEN     997    997       W->L: No effect on RT p66/p51
FT                                heterodimerization.
FT                                {ECO:0000269|PubMed:12559908}.
FT   MUTAGEN    1000   1000       W->A: Almost complete loss of RT p66/p51
FT                                heterodimerization. Complete loss of
FT                                polymerase activity.
FT                                {ECO:0000269|PubMed:12559908,
FT                                ECO:0000269|PubMed:15852304}.
FT   MUTAGEN    1000   1000       W->F: No effect on RT p66/p51
FT                                heterodimerization.
FT                                {ECO:0000269|PubMed:12559908,
FT                                ECO:0000269|PubMed:15852304}.
FT   MUTAGEN    1000   1000       W->L: Almost complete loss of RT p66/p51
FT                                heterodimerization. Complete loss of
FT                                polymerase activity.
FT                                {ECO:0000269|PubMed:12559908,
FT                                ECO:0000269|PubMed:15852304}.
FT   MUTAGEN    1001   1001       W->L: No effect on RT p66/p51
FT                                heterodimerization.
FT                                {ECO:0000269|PubMed:12559908}.
FT   MUTAGEN    1004   1004       Y->L: No effect on RT p66/p51
FT                                heterodimerization.
FT                                {ECO:0000269|PubMed:12559908}.
FT   MUTAGEN    1005   1005       W->L: Decreased RT p66/p51
FT                                heterodimerization.
FT                                {ECO:0000269|PubMed:12559908}.
FT   MUTAGEN    1009   1009       W->L: No effect on RT p66/p51
FT                                heterodimerization.
FT                                {ECO:0000269|PubMed:12559908}.
FT   MUTAGEN    1013   1013       W->L: Almost complete loss of RT p66/p51
FT                                heterodimerization.
FT                                {ECO:0000269|PubMed:12559908}.
FT   MUTAGEN    1036   1036       A->I: Replication slightly delayed.
FT                                {ECO:0000269|PubMed:16140771}.
FT   MUTAGEN    1037   1037       E->N: Virions contain primarily p51 RT.
FT                                {ECO:0000269|PubMed:16140771}.
FT   MUTAGEN    1038   1038       T->S: Almost complete loss of virion
FT                                production; when associated with G-1041.
FT                                {ECO:0000269|PubMed:16140771}.
FT   MUTAGEN    1039   1039       F->A: Virions contain primarily p51 RT.
FT                                {ECO:0000269|PubMed:16140771,
FT                                ECO:0000269|PubMed:2044756}.
FT   MUTAGEN    1039   1039       F->I: Loss of cleavage between p51 RT and
FT                                p15. {ECO:0000269|PubMed:16140771,
FT                                ECO:0000269|PubMed:2044756}.
FT   MUTAGEN    1039   1039       F->L: No effect on cleavage between p51
FT                                RT and p15. {ECO:0000269|PubMed:16140771,
FT                                ECO:0000269|PubMed:2044756}.
FT   MUTAGEN    1039   1039       F->V: Slight delays in replication.
FT                                Virions contain primarily p51 RT.
FT                                {ECO:0000269|PubMed:16140771,
FT                                ECO:0000269|PubMed:2044756}.
FT   MUTAGEN    1039   1039       F->W: Slight delays in replication.
FT                                Virions contain primarily p51 RT.
FT                                {ECO:0000269|PubMed:16140771,
FT                                ECO:0000269|PubMed:2044756}.
FT   MUTAGEN    1040   1040       Y->A: Virions contain primarily p51 RT;
FT                                when associated with A-1039.
FT                                {ECO:0000269|PubMed:16140771}.
FT   MUTAGEN    1040   1040       Y->I: Almost complete loss of virion
FT                                production; when associated with K-1041.
FT                                {ECO:0000269|PubMed:16140771}.
FT   MUTAGEN    1040   1040       Y->W: Virions contain primarily p51 RT;
FT                                when associated with W-1039.
FT                                {ECO:0000269|PubMed:16140771}.
FT   MUTAGEN    1041   1041       V->G: Almost complete loss of virion
FT                                production; when associated with S-1038.
FT                                {ECO:0000269|PubMed:16140771}.
FT   MUTAGEN    1041   1041       V->K: Almost complete loss of virion
FT                                production; when associated with I-1038.
FT                                {ECO:0000269|PubMed:16140771}.
FT   MUTAGEN    1041   1041       V->S: Slight delays in replication.
FT                                {ECO:0000269|PubMed:16140771}.
FT   MUTAGEN    1077   1077       E->Q: No loss of polymerase activity.
FT                                complete loss of RNase H activity.
FT                                {ECO:0000269|PubMed:9533880}.
FT   MUTAGEN    1100   1100       Y->A,G,H,L,S,Q: Complete loss of RNAase H
FT                                activity. {ECO:0000269|PubMed:11684697}.
FT   MUTAGEN    1100   1100       Y->E: Almost complete loss of RNAase H
FT                                activity. {ECO:0000269|PubMed:11684697}.
FT   MUTAGEN    1100   1100       Y->F: Almost no effect on RNAase H
FT                                activity and replication.
FT                                {ECO:0000269|PubMed:11684697}.
FT   MUTAGEN    1100   1100       Y->R: Almost no effect on RNAase H
FT                                activity. Unable to replicate. Completely
FT                                resistant to inhibition by BBNH.
FT                                {ECO:0000269|PubMed:11684697}.
FT   MUTAGEN    1100   1100       Y->W: Almost no effect on RNAase H
FT                                activity and replication. 6-fold
FT                                resistance to inhibition by BBNH.
FT                                {ECO:0000269|PubMed:11684697}.
FT   MUTAGEN    1138   1138       H->D,N: Severely reduces exonuclease
FT                                activity of RNase H. Probably also
FT                                reduces substrate binding affinity.
FT                                Modifies cleavage preferences of RNase H.
FT                                No effect on the endonuclease activity.
FT                                {ECO:0000269|PubMed:1714505}.
FT   MUTAGEN    1138   1138       H->D: Severely reduced exonuclease
FT                                activity of RNase H, but no effect on
FT                                endonucleonuclease activity.
FT                                {ECO:0000269|PubMed:1714505}.
FT   MUTAGEN    1138   1138       H->N: Severely reduced exonuclease
FT                                activity of RNase H, but no effect on
FT                                endonucleonuclease activity.
FT                                {ECO:0000269|PubMed:1714505}.
FT   MUTAGEN    1159   1159       L->F: No effect on cleavage between
FT                                reverse transcriptase/ribonuclease H and
FT                                integrase. {ECO:0000269|PubMed:2044756}.
FT   MUTAGEN    1159   1159       L->I: Loss of cleavage between reverse
FT                                transcriptase/ribonuclease H and
FT                                integrase. {ECO:0000269|PubMed:2044756}.
FT   TURN        393    395       {ECO:0000244|PDB:2EXF}.
FT   STRAND      398    400       {ECO:0000244|PDB:2EXF}.
FT   TURN        402    404       {ECO:0000244|PDB:2EXF}.
FT   STRAND      414    416       {ECO:0000244|PDB:2EXF}.
FT   STRAND      419    421       {ECO:0000244|PDB:2EXF}.
FT   TURN        423    425       {ECO:0000244|PDB:2EXF}.
FT   STRAND      426    429       {ECO:0000244|PDB:2L4L}.
FT   STRAND      502    504       {ECO:0000244|PDB:1MER}.
FT   STRAND      505    507       {ECO:0000244|PDB:3NU3}.
FT   STRAND      510    515       {ECO:0000244|PDB:3NU3}.
FT   STRAND      518    524       {ECO:0000244|PDB:3NU3}.
FT   STRAND      529    533       {ECO:0000244|PDB:3NU3}.
FT   STRAND      542    549       {ECO:0000244|PDB:3NU3}.
FT   STRAND      552    566       {ECO:0000244|PDB:3NU3}.
FT   STRAND      569    578       {ECO:0000244|PDB:3NU3}.
FT   STRAND      581    585       {ECO:0000244|PDB:1NPA}.
FT   HELIX       587    590       {ECO:0000244|PDB:3NU3}.
FT   TURN        591    594       {ECO:0000244|PDB:3NU3}.
FT   STRAND      596    598       {ECO:0000244|PDB:3NU3}.
FT   STRAND      602    604       {ECO:0000244|PDB:1S9G}.
FT   STRAND      611    614       {ECO:0000244|PDB:4I2Q}.
FT   HELIX       627    642       {ECO:0000244|PDB:4G1Q}.
FT   STRAND      645    648       {ECO:0000244|PDB:4G1Q}.
FT   STRAND      651    653       {ECO:0000244|PDB:1S9E}.
FT   STRAND      659    663       {ECO:0000244|PDB:4G1Q}.
FT   STRAND      665    668       {ECO:0000244|PDB:4G1Q}.
FT   STRAND      670    674       {ECO:0000244|PDB:4G1Q}.
FT   HELIX       677    682       {ECO:0000244|PDB:4G1Q}.
FT   HELIX       684    687       {ECO:0000244|PDB:4PQU}.
FT   HELIX       689    691       {ECO:0000244|PDB:4ICL}.
FT   HELIX       696    698       {ECO:0000244|PDB:4G1Q}.
FT   HELIX       699    701       {ECO:0000244|PDB:4G1Q}.
FT   STRAND      703    709       {ECO:0000244|PDB:4G1Q}.
FT   HELIX       710    712       {ECO:0000244|PDB:3ITH}.
FT   HELIX       713    716       {ECO:0000244|PDB:4G1Q}.
FT   HELIX       721    727       {ECO:0000244|PDB:4G1Q}.
FT   STRAND      729    731       {ECO:0000244|PDB:4G1Q}.
FT   HELIX       734    736       {ECO:0000244|PDB:4G1Q}.
FT   STRAND      737    739       {ECO:0000244|PDB:1S9G}.
FT   STRAND      741    747       {ECO:0000244|PDB:4G1Q}.
FT   STRAND      752    754       {ECO:0000244|PDB:3IG1}.
FT   HELIX       755    773       {ECO:0000244|PDB:4G1Q}.
FT   STRAND      774    776       {ECO:0000244|PDB:3V6D}.
FT   STRAND      777    782       {ECO:0000244|PDB:4G1Q}.
FT   STRAND      785    790       {ECO:0000244|PDB:4G1Q}.
FT   HELIX       794    808       {ECO:0000244|PDB:4G1Q}.
FT   HELIX       809    811       {ECO:0000244|PDB:4G1Q}.
FT   HELIX       816    818       {ECO:0000244|PDB:4O44}.
FT   STRAND      819    823       {ECO:0000244|PDB:2B6A}.
FT   STRAND      824    828       {ECO:0000244|PDB:4G1Q}.
FT   STRAND      831    833       {ECO:0000244|PDB:4G1Q}.
FT   HELIX       835    837       {ECO:0000244|PDB:4G1Q}.
FT   STRAND      838    841       {ECO:0000244|PDB:4G1Q}.
FT   STRAND      849    852       {ECO:0000244|PDB:2ZD1}.
FT   HELIX       853    866       {ECO:0000244|PDB:4G1Q}.
FT   TURN        867    869       {ECO:0000244|PDB:4G1Q}.
FT   STRAND      870    872       {ECO:0000244|PDB:1DLO}.
FT   HELIX       876    879       {ECO:0000244|PDB:4G1Q}.
FT   HELIX       880    882       {ECO:0000244|PDB:4G1Q}.
FT   TURN        883    885       {ECO:0000244|PDB:4O4G}.
FT   STRAND      886    888       {ECO:0000244|PDB:3IS9}.
FT   STRAND      890    892       {ECO:0000244|PDB:1QE1}.
FT   HELIX       896    908       {ECO:0000244|PDB:4G1Q}.
FT   STRAND      909    911       {ECO:0000244|PDB:3IS9}.
FT   STRAND      913    916       {ECO:0000244|PDB:3DLK}.
FT   STRAND      920    922       {ECO:0000244|PDB:2BE2}.
FT   STRAND      925    932       {ECO:0000244|PDB:4G1Q}.
FT   STRAND      935    943       {ECO:0000244|PDB:4G1Q}.
FT   STRAND      946    954       {ECO:0000244|PDB:4G1Q}.
FT   STRAND      957    961       {ECO:0000244|PDB:4G1Q}.
FT   HELIX       963    982       {ECO:0000244|PDB:4G1Q}.
FT   STRAND      987    992       {ECO:0000244|PDB:4G1Q}.
FT   HELIX       994   1003       {ECO:0000244|PDB:4G1Q}.
FT   STRAND     1004   1006       {ECO:0000244|PDB:3DLK}.
FT   STRAND     1012   1015       {ECO:0000244|PDB:4G1Q}.
FT   STRAND     1017   1019       {ECO:0000244|PDB:3HVT}.
FT   STRAND     1020   1022       {ECO:0000244|PDB:3V81}.
FT   HELIX      1023   1026       {ECO:0000244|PDB:4G1Q}.
FT   STRAND     1029   1031       {ECO:0000244|PDB:1HQU}.
FT   STRAND     1036   1045       {ECO:0000244|PDB:4G1Q}.
FT   TURN       1047   1049       {ECO:0000244|PDB:4G1Q}.
FT   STRAND     1052   1058       {ECO:0000244|PDB:4G1Q}.
FT   STRAND     1059   1061       {ECO:0000244|PDB:1HQE}.
FT   STRAND     1063   1070       {ECO:0000244|PDB:4G1Q}.
FT   HELIX      1073   1087       {ECO:0000244|PDB:4G1Q}.
FT   STRAND     1090   1096       {ECO:0000244|PDB:4G1Q}.
FT   HELIX      1099   1105       {ECO:0000244|PDB:4G1Q}.
FT   STRAND     1110   1114       {ECO:0000244|PDB:4G1Q}.
FT   HELIX      1115   1126       {ECO:0000244|PDB:4G1Q}.
FT   STRAND     1128   1134       {ECO:0000244|PDB:4G1Q}.
FT   STRAND     1137   1139       {ECO:0000244|PDB:2ZD1}.
FT   STRAND     1140   1142       {ECO:0000244|PDB:1SUQ}.
FT   HELIX      1144   1152       {ECO:0000244|PDB:4G1Q}.
FT   TURN       1153   1155       {ECO:0000244|PDB:4QAG}.
FT   STRAND     1219   1227       {ECO:0000244|PDB:3AVI}.
FT   STRAND     1230   1237       {ECO:0000244|PDB:3AVI}.
FT   TURN       1238   1240       {ECO:0000244|PDB:3AVI}.
FT   STRAND     1243   1250       {ECO:0000244|PDB:3AVI}.
FT   HELIX      1253   1266       {ECO:0000244|PDB:3AVI}.
FT   STRAND     1271   1273       {ECO:0000244|PDB:3AVI}.
FT   HELIX      1277   1281       {ECO:0000244|PDB:3AVI}.
FT   HELIX      1283   1292       {ECO:0000244|PDB:3AVI}.
FT   STRAND     1295   1297       {ECO:0000244|PDB:3AVI}.
FT   HELIX      1305   1324       {ECO:0000244|PDB:3AVI}.
FT   HELIX      1325   1327       {ECO:0000244|PDB:3AVI}.
FT   HELIX      1331   1344       {ECO:0000244|PDB:3AVI}.
FT   HELIX      1355   1367       {ECO:0000244|PDB:3AVI}.
FT   STRAND     1380   1386       {ECO:0000244|PDB:1QMC}.
FT   STRAND     1395   1403       {ECO:0000244|PDB:1QMC}.
FT   STRAND     1405   1420       {ECO:0000244|PDB:1QMC}.
FT   HELIX      1421   1423       {ECO:0000244|PDB:1QMC}.
FT   STRAND     1424   1428       {ECO:0000244|PDB:1QMC}.
FT   HELIX      1436   1439       {ECO:0000244|PDB:1BQN}.
SQ   SEQUENCE   1447 AA;  163288 MW;  AC3EE1439592E0AD CRC64;
     MGARASVLSG GELDRWEKIR LRPGGKKKYK LKHIVWASRE LERFAVNPGL LETSEGCRQI
     LGQLQPSLQT GSEELRSLYN TVATLYCVHQ RIEIKDTKEA LDKIEEEQNK SKKKAQQAAA
     DTGHSSQVSQ NYPIVQNIQG QMVHQAISPR TLNAWVKVVE EKAFSPEVIP MFSALSEGAT
     PQDLNTMLNT VGGHQAAMQM LKETINEEAA EWDRVHPVHA GPIAPGQMRE PRGSDIAGTT
     STLQEQIGWM TNNPPIPVGE IYKRWIILGL NKIVRMYSPT SILDIRQGPK EPFRDYVDRF
     YKTLRAEQAS QEVKNWMTET LLVQNANPDC KTILKALGPA ATLEEMMTAC QGVGGPGHKA
     RVLAEAMSQV TNTATIMMQR GNFRNQRKMV KCFNCGKEGH TARNCRAPRK KGCWKCGKEG
     HQMKDCTERQ ANFLREDLAF LQGKAREFSS EQTRANSPTI SSEQTRANSP TRRELQVWGR
     DNNSPSEAGA DRQGTVSFNF PQITLWQRPL VTIKIGGQLK EALLDTGADD TVLEEMSLPG
     RWKPKMIGGI GGFIKVRQYD QILIEICGHK AIGTVLVGPT PVNIIGRNLL TQIGCTLNFP
     ISPIETVPVK LKPGMDGPKV KQWPLTEEKI KALVEICTEM EKEGKISKIG PENPYNTPVF
     AIKKKDSTKW RKLVDFRELN KRTQDFWEVQ LGIPHPAGLK KKKSVTVLDV GDAYFSVPLD
     EDFRKYTAFT IPSINNETPG IRYQYNVLPQ GWKGSPAIFQ SSMTKILEPF KKQNPDIVIY
     QYMDDLYVGS DLEIGQHRTK IEELRQHLLR WGLTTPDKKH QKEPPFLWMG YELHPDKWTV
     QPIVLPEKDS WTVNDIQKLV GKLNWASQIY PGIKVRQLCK LLRGTKALTE VIPLTEEAEL
     ELAENREILK EPVHGVYYDP SKDLIAEIQK QGQGQWTYQI YQEPFKNLKT GKYARMRGAH
     TNDVKQLTEA VQKITTESIV IWGKTPKFKL PIQKETWETW WTEYWQATWI PEWEFVNTPP
     LVKLWYQLEK EPIVGAETFY VDGAANRETK LGKAGYVTNK GRQKVVPLTN TTNQKTELQA
     IYLALQDSGL EVNIVTDSQY ALGIIQAQPD KSESELVNQI IEQLIKKEKV YLAWVPAHKG
     IGGNEQVDKL VSAGIRKILF LDGIDKAQDE HEKYHSNWRA MASDFNLPPV VAKEIVASCD
     KCQLKGEAMH GQVDCSPGIW QLDCTHLEGK VILVAVHVAS GYIEAEVIPA ETGQETAYFL
     LKLAGRWPVK TIHTDNGSNF TSATVKAACW WAGIKQEFGI PYNPQSQGVV ESMNKELKKI
     IGQVRDQAEH LKTAVQMAVF IHNFKRKGGI GGYSAGERIV DIIATDIQTK ELQKQITKIQ
     NFRVYYRDSR NPLWKGPAKL LWKGEGAVVI QDNSDIKVVP RRKAKIIRDY GKQMAGDDCV
     ASRQDED
//
